恶性肿瘤神经—内分泌—免疫网络紊乱的维西医研究
|
摘要
随着细胞生物学、分子生物学以及基因组学等基础研究的发展，癌症的发病机制和临床治疗方面取得了长足的进步，某些恶性肿瘤，如早期宫颈癌、乳腺癌等已可达到根治。但是多数恶性肿瘤的治疗迄今未根本解决。即使治愈率很高的恶性肿瘤在治疗后部分病人在若干年后还会有远处转移。科学家们从基因组学等更微观的层次研究癌症，无疑对揭示其发病机制和治愈癌症有着十分重要的作用。但是毕竟生命活动和疾病的发生、发展不能仅仅用单个细胞、单个基因发生改变解释，应该从机体的稳态和整体出发。神经-内分泌-免疫网络(Neuro-endocrine-immune，NEI)概念的精髓是机体通过神经、内分泌和免疫三大相互独立又密不可分的系统维持着机体的稳态和平衡。它们之间相互作用是通过神经递质、激素和细胞因子介导。这个网络中的任何一个环节出现严重失衡，都会明显影响其他系统的功能，导致相关疾病的发生。早在1984年Rosch提出，机体的激素水平和免疫状况是影响肿瘤生长的两种最主要的内在因素。但是，总体上整个机体对肿瘤发生、发展的重要性没有得到足够的重视，更没有成为肿瘤治疗的主流。癌症既然是细胞异常生长为特征的疾病，机体对细胞生长的调节系统应是多方位、多层次的。
维吾尔医学历来非常重视人体本身的统一性、完整性及其与自然界的相互联系，认为人体是一个有机整体，构成人体的各个脏器、组织或器官，在结构上是不可分割的。维吾尔医关于体液论有如下的阐
With the development of the cytobiology and molecular biology, pathogenesis and therapy of cancer have been improved, some caners like early stage cervical cancer and breast cancer can be cured. However, the fundamental therapy in most of them is still undone. Some cancer inevitably metastasizes after radical cure. Genomics research from microcosmic plays an important role in revealing the pathogenesis and therapy of cancer. But vital movement and diseases couldn't be explained by sing cell, or gene, the homeostasis of organism should be emphasized. The essence of the neuro-endocrine-immune network is to keep the homeostasis and balance of organism by the three interdependent systems-nervous, endocrine and immune system. The interaction between them is mediated by the nervous transmitters, hormones and cytokines. Any part disbalance of the network must obviously impair other's function and lead to disorder. In 1984, Rosch pointed out that environmental carcinogenic agent was responsible for the cancer via physical and chemical agents; meanwhile the level of hormones and cytokines were the most important internal agents for regulating the development of cancer. The disorder of the neuro-endocrine-immune was involved in many malignant carcinomas carcinogens and development. Now that cancer is characterized by the cellular abnormal growth, the
维吾尔医学历来非常重视人体本身的统一性、完整性及其与自然界的相互联系，认为人体是一个有机整体，构成人体的各个脏器、组织或器官，在结构上是不可分割的。维吾尔医关于体液论有如下的阐
With the development of the cytobiology and molecular biology, pathogenesis and therapy of cancer have been improved, some caners like early stage cervical cancer and breast cancer can be cured. However, the fundamental therapy in most of them is still undone. Some cancer inevitably metastasizes after radical cure. Genomics research from microcosmic plays an important role in revealing the pathogenesis and therapy of cancer. But vital movement and diseases couldn't be explained by sing cell, or gene, the homeostasis of organism should be emphasized. The essence of the neuro-endocrine-immune network is to keep the homeostasis and balance of organism by the three interdependent systems-nervous, endocrine and immune system. The interaction between them is mediated by the nervous transmitters, hormones and cytokines. Any part disbalance of the network must obviously impair other's function and lead to disorder. In 1984, Rosch pointed out that environmental carcinogenic agent was responsible for the cancer via physical and chemical agents; meanwhile the level of hormones and cytokines were the most important internal agents for regulating the development of cancer. The disorder of the neuro-endocrine-immune was involved in many malignant carcinomas carcinogens and development. Now that cancer is characterized by the cellular abnormal growth, the
引文
[1] 于尔辛，汤钊献，朱世能．现代肿瘤学．上海．上海医科大学出版社，1993．1-7
[2] 孙燕．实用肿瘤内科学．北京：人民卫生出版社，1999．161-165
[3] 顾健人，杨胜利．要用系统性疾病的观念重新认识癌症．中华医学杂志．2005，85(8)：505-507
[4] Besedovsky H, et al. Network of immune-neuroendocrine interactions[J]. Clin Exp Immunol. 1977, 27:1
[5] BLALOCK, J. E. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol. Rev. 1989, 69:1-32
[6] SMITH, M, A, S. MAKINO, S. Y. KIM, AND R. KVETNANSKY. Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 1995, 136:3743-3750
[7] WEIGENT, D. A., J. E. BLALOCK. Production of peptide hormones and neurotransmitters by the immune system. Chem. Immunol. 1997, 69:1-30
[8] OTTAVIANI, E., E. CASELGRANDI, F. PETRAGLIA, AND C. FRANCESCHI. Stress response in the freshwater snail Planobarius corneus (L.) (gastropoda, pulmonata): interaction between CRF, ACTH, and biogenic amines. Gen. Comp. Endocrinol. 1992, 87:354-360
[9] Rosch P J. Stress and cancer. In: Cary L Cooper. Psychosocial Stress and Cancer. Jone Wiley & Sons L td, 1984
[10] Bodey B, Siegel SE. Mechanisms and markers of carcinogenesis and neoplastic progression[J]. Expert Opin Ther, 2005, 5(10): 1371-32
[11] Price MA, Tennant CC, Buttow PN, et al. The role of psychosocial factors in the development of breast carcinoma: Part II. Life event stressor. Social support, defense style , and emotional control and their interactions [J]. Cancer, 2001, 91(4): 686-697
[12] Prolo P. Neuroendocrien -immune Surveillance of Osteosarcoma; Emerging Hypothesis [J]. J Dent Res, 2003, 82(6): 417-21
[13] Rowse GL, Weiunberg J, Bellward GD, et al. Endocrine medication of psychosocial stressor effects on mouse mammary tumor growth [J]. Cancer Lett, 1992, 65; 85-93
[14] Lonitier P, Wildrick DM, Boman BM. The effects of steroids hormones on a human colon cancer line in vitro [J]. Anticancancer Res, 1992, 12: 1327-30
[15] Snoussi K, Strosberg AD, Ben Ahmed S, et al. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1 alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw. 2005; 16(4):253-260
[16] Crippa S, Mussi C, Angelini C, et al. Alteration of hypothalamus-pituitary-adrenal gland axis in colorectal cancer patients. Preliminary report. Minerva Chir. 2003 Aug; 58(4): 581-585
[17] Mazzoccoli G, Carughi S, De Cata A, et al. Neuroendocrine alterations in lung cancer patients. Neuro Endocrinol Lett. 2003 Feb-Apr;24(1-2):77-82
[18] Rutkowski P, Kaminska J, Kowalska M, et al. Cytokines serum levels in softtissure sarcoma patients: correlations with clincio-pathological features and prognosis. Int J Cancer. 2002 Aug1; 100(4):463-71
[19] Lee E, Shin YJ, Chong YH. Mechanisms involved in p rostaglandin E2-mediated neurop rotection against TNF-alpha: possible involvement of multip le signal transduction and beta-catenin /T-cell factor. J Immunol, 2004, 155: 21-31
[20] Gruber2Olip iz M, Stevenson R, Olip iz W, et al. Transcriptional pattern analysis of adrenergic immunoregulation in mice. Twelve hours norepinephrine treatment alters the expression of a set of genes involved in monocyte activation and leukocyte trafficking. J Immunol, 2004, 155: 136-142
[21] Nave H, Bedoui S, Moenter F, et al. Reduced tissue immigration of monocytes by neuropep tide Y during endotoxemia is associated with Y-receptor activation. J Neuroimmunol, 2004, 155: 1212
[22] MORGAN, J. I., AND T. CURRAN. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 1991,14: 421-451
[23] RIVIER.C, AND W. VALE. Interaction of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on ACTH secretion in vivo. Endocrinology .1983; 113: 939-942
[24] SAWCHENKO, P. E., L. W. SWANSON, AND W. W. VALE. Co-expression of CRF-and vasopressin-immunoreactivity in parvocellular neurosecretory neurons in the adrenalectomized rat. Proc. Natl. Acad. Sci. USA.1984; 81: 1883-1887
[25] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, A. J. CHOVER-GONZALEZ, AND S. L. LIGHTMAN. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992; 6: 214-222
[26] CURTI, B. D., W. J. URBA, D. L. LONGO, et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996; 19:142-148
[27] KOIV, L., E. MERISALU, K. ZILMER, et al. Changes of sympatho-adrenal and hypothalamo-pituitary-adrenocortical system in patients with head injury. Acta Neurol. Scand. 1997; 96: 52-58
[28] FASSBENDER, K., R. SCHMIDT, R. MOSSNER, et al. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 1994;25:1105-1108
[29] HARBUZ, M. S., G. L. CONDE, O. MARTI, et al. The hypothalamic-pituitary-adrenal axis in autoimmunity. Ann. NY Acad. Sci. 1997;823:214-224
[30] LEMAY, L. G., A. J. VANDER, M. J. KLUGER. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol. Behav. 1990;47:957-961
[31] MEKAOUCHE, M., L. GIVALOIS, G. BARBANEL, et al. Chronic restraint enhances interleukin-l-beta release in the basal state and after an endotoxin challenge, independently of adrenocorticotropin and corticosterone release. Neuroimmunomo-dulation 1994; 1: 292-299
[32] Haddad J J, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2): 154
[33] 易沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册，第一册．乌鲁木齐：新疆人民出版社．1988，第一版
[34] 哈木拉提·吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，51-52
[35] 哈木拉提·吾甫尔．维吾尔医气质、体液论及其现代研究[M]．2003，131-133
[36] 努尔买买提，哈木拉提·吾甫尔等．异常黑胆质成熟剂和清除剂对小鼠神内分泌免疫网络的的调节作用研究[C]．维吾尔医药及其他传统医学研究与应用；乌鲁木齐：新疆人民卫生出版社，2003年，11-12
[37] 易沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册，第六册．乌鲁木齐：新疆科技卫生出版社．1995，第一版
[38] Greer S. Psychoneuroimmunology: interaction between the nervous system and the immune system. Lancet, 1995, 345(8942): 99-103
[39] Kiecolt Glaser JK, Glaser R. Psychoneuroimmunology and cancer: factor and fiction. Eur, Cancer. 1999, 36(11): 1603-1607
[40] SabbioniM. Cancer and stress: A possible role for psychoneuroimmunoloy in cancer research in: C L Cooper, M Watson. Cancer and Stress: Psycholoical, Biological and Cop in. Studies. JohnW iley & Sons L td, 1991
[41] Ippoliti F, N atalia SM, PozziV, et- al. Psycho logical behavior and immunodep ression in women with breast cancer, Congress on Brain and Immunity. Acta- N euro lo.ica, 1991, 13 (5): 483-490
[42] De BrabanderB, Haeseleer F D, De BrabanderM, et- al. The protective effect of behavioral activation on the growth of a syngeneic tumo r and mortality in socially stressed mice. European Journal of Psychiatry, 1989, 3(4): 238-244
[43] Ben Eliyahu S, Yirm iya R, L iebesk J C, et- al. Stress increase metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. Brain, Behavior and Immunity, 1991, 5 (2):193-205
[44] A der R, Cohen N. P sychoneuroimmunology: Conditionin and stress. Annu. Rev. P sycho 1, 1993, 44:53-85
[45] 潘菊芬．神经内分泌与免疫系统[M]．见：张殿明，徐隆绍主编．神经内分泌学．第1版．北京：中国医药科技出版社，1991．349-355
[46] Esquifino A I, Chacon F, Cano P, et al. Twenty2four2hour rhythms of mitogenic responses, lymphocyte subset populations and amino acid content in submaxillary lymph nodes of growingmale rats subjected to calorie restriction. Immunol, 2004, 156: 66-73
[47] Wilder R. Neuroendocrine-immune system interactions and auto immunity. Annu Rev Immunol, 1995, 13:307-312
[48] Cullinan WE, Herman JP, Watson SJ. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis [J]. J Comp Neurol,1993, 332 :1-20
[49] Lechin F, Van der Dijis B, Vitelli F G, et- al. Psychoneuro-endocrineological and immunological parameters in cancer patients: Involovement of stress and depression. Psychoneuroendocrinology, 1990, 15(5-6):435-451
[50] Berghella AM, Pellegrini P, Del Beato T et al.: The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 toTH2 and back. Cancer Immunol Immunotherapy. 1998, 45: 241-249
[51] Dinarello CA. Biologic basis for Interleukin 1 in disease. Blood, 1996, 87:2095-2147
[52] VAN DER MEER, SWEEP, G. J. PESMAN, F. J.H.et al. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine 1996, 8:910-919
[53] MATTA, S. G, K. M. LINNER, AND B. M. SHARP. Interleukin-1β and interleukin-1β stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology 1993.57:14-22
[54] NAITO, Y., J. FUKATA, T. TOMINAGA, et al. Adrenocorticotropic hormone releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res. Commun. 1989,164:1262-1267
[55] 朱晓琴，李正莉，朱长庚．IL-1α或IL-6对大脑皮质星形胶质细胞细胞周期的影响[J]．神经解剖学杂志．2005，21(3)：313-316
[56] Anna CSISZAR, Tamás SZENTES, Bea HARASZTI,et al.The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004, 10(2):109-116
[57] Ogata A, Nishimoto N, Yoshizaki K. Advances in interleukin-6 therapy[J]. Rinsho Byori, 1999, 47 (4):321-326
[58] Nakashima K, Taga T. Gpl30 and the IL26 family of cytokines: signaling mechanisms and thrombopoietic activities[J].1 Semin Hematol, 1998, 35(3):2102-2211
[59] Villunger A, Egle A, Kos M, et al. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies[J]. Int J Cancer, 1996, 65(4):498-505
[60] Giometto B, Bozza F, Faresin F, et al. Immune infiltrates and cytokines in gliomas[J]. Acta Neurochir Wien, 1996, 138(1): 502-561
[61] Galvani V, Pret nar H K, Rup reht R R, et al. Soluble tumor necrosis factor receptor I (s TNFRI) as a prognostic f act or in melanoma patients in Slovene population[J]. Pf lugers Arch, 2000; 440 (5 Suppl):R61-63
[62] Libura J, Bet tens F, Radkowski A, et al. Polymorp hictumor necrosis f acter microsatellite TNFα 4 is associated wit h resistance of Hodgkin lymphoma t o chemotherapy and wit h relapses after therapy[J]. Anticancer Res, 2002, 22(2A):921-926
[63] James F. Holland, Emil Frei Ⅲ, Robert C. Bast. Cancer Medicine (Sth edition). Jr.Willian & wilkins, 2000
[64] Li J, Kelsey S M, Grahn M F, et al. Increased activity andsensitivity of mitochondrial respi rat oryenzymes t o tumor necrosis facter -α mediated inhibition is associated wit h increased cytotoxicity in drug resistant leukemic cell lines[J]. Blood, 1996,87(6):2401-2410
[65] Stein U, Walt her W, Laurencot C M, et al. Tumor necrosis facter alpha and expression of the multidrug resistance associated genes L RP and MRP[J]. J Natl Cancer Inst, 1997, 89(11):807-813
[66] 粟毅，吴亚梅．肿瘤坏死因子与白细胞介素2协同抑制肺腺癌细胞的研究．癌症．2000，19(8)：779-781
[67] W u S, Boyer CM, W h itaker RS, et al. Tumo r necro sis facto r Aas an autocrine and paracrine grow the factor for ovarianancer: Monok ine induct ion of tumor cell pro liferation and tumor necrosis factor A expression. Cancer Res, 1993; 53:1939
[68] Tamás SZENTES, Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2005; 11(2):124-130
[69] Takagi K, Tomita K, Fukushima, et al: Endogenous TNF inducibility and prognosis of colorectal cancer. Anticancer Res. 1998, 18:4141-4146
[70] Anna CSISZAR, Tamás SZENTES, Bea HARASZTI, et al. The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004; 10(2):109-116
[71] 汤钊主编，现代肿瘤学[M]．上海：上海医科大学出版社，1993，6：121-139
[72] 吕先科，玉寒冰，霍晓君，等．肺癌患者血清免疫抑制酸性蛋白及T细胞亚群联合检测的意义[J]．上海免疫学杂志，1999，19(3)：177
[73] 秦建国，韩本立，潘世春．原发性肝癌患者T淋巴细胞亚群及功能 变化在肿瘤复发中的临床意义[J]．中华实验外科杂志，1998，15(1)：11
[74] 王毅鑫，阮灿平，李莉，等．胃癌患者手术前后T细胞及其活化抗原表达的变化与临床意义[J]．上海免疫学杂志，1998，18(4)：228
[75] 程邦昌，陈克能，梅强，等．食管癌患者外周血T淋巴细胞亚群、肿瘤坏死因子的改变及其相关因素研究[J]．中华实验外科杂志，1998，19(3)：226
[76] Lin Z, Madras BK. Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol. 2006; 1(75):327-71
[77] Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005 Dec 20; 7(4):E847-51
[78] 张锦培，黄兴兵，关念红等．广泛性焦虑症与抑郁症棉衣、内分泌及单胺递质的对照研究[J]．中华精神科杂志．2004；37(4)：211-214
[79] Mazzoccoli G, Grilli M, Carughi S,et al. Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol, 2003; 16(2):167-174
[80] 李广太．妇科肿瘤患者外周血淋巴细胞亚群研究．中国肿瘤临床，1996，23(7)：505
[81] Rotstein. Int J Radiat Oncol Biol Phys. 1985; 11:921
[82] Shunjun, Yang. Radiology. 1988. 168:537
[83] Gregory T Wolf. Arch Otolaryngol. 1985; 111:716
[84] 周决，曹世龙．放疗后机体免疫功能改变初探[J]．上海面医学杂志．1996；11(1)：22-24
[85] Carleton C Stewant. Int J Radiat Oncol Biol Phys. 1988; 55:77
[86] 杜鹃，何执鼎．恶性肿瘤患者及化疗后外周血T淋巴细胞亚群的检测[J]．中国医师杂志，2003，5(4)：540-541
[87] 汤钊猷主编．现代肿瘤学[M]．上海医科大学出版社，1993，6：121-131
[88] 施靖华，陈腾，陈兆瑞．手术及化疗对胃癌患者免疫功能的影响[J]．第二军医大学学报，1995，16(5)：454-457
[89] 梁靖，李艳，刘晓玲等．化疗对结肠癌患者Th1和Th2类细胞因子表达的影响及意义．中国肿瘤临床．2006；33(6)：916-919
[90] 姚树坤，李洪祥，李星涛，等．恶性肿瘤患者化疗前后细胞免疫功能的监测[J]．中华物理医学杂志，1995，17(2)：84-861
[91] Nlulgl Mazzoccoll, Stefano Carughl, Angelo De Cata, et al. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit, 2005; 11(6): CR284-288
[92] Mussi C, Angelini C, Crippa S. Alteration of hypothalamus-pituitary-adrenal glands axis in colorectal cancer patients. Hepatogastroenterology. 2003; 50 Suppl 2: ccxxviii-ccxxxi
[93] Giovanni Mantovani, Clelia Madeddu, Antonio Macciò, et al.Cancer-Related Anorexia/Cachexia Syndrome and Oxidative Stress: An Innovative Approach beyond Current Treatment. Cancer Epidemiology Biomarkers & Prevention 2004; 13:1651-1659
[94] Crippa S, Mussi C, Angelini C, et al. Alteration of hypothalamus-pituitary-adrenal gland axis in colorectal cancer patients. Preliminary report. Minerva Chir. 2003 Aug; 58(4):581-585
[95] 伊沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册M]，第一册。乌鲁木齐：新疆人民卫生出版社．1988．第一版
[96] 买买提明．沙比尔．维吾尔医学诊断学[M]．乌鲁木齐：新疆科技卫生出版社，1993
[97] OTTAVIANI, E., AND C. FRANCHESCHI. The invertebrate phagocytic immunocyte: clues to a common evolution of immune and neuroendocrine systems. Immunol. Today 1997, 18:169-174
[98] Wang D. RusseU J,Xu H. Deregulated expreeon of DPI induces epidermis proliferation and enhances in skin carcinoma. JMolCarcinog. 2001, 31(2): 90-100
[99] 哈木拉提．吾甫尔，艾斯卡尔．依米提，伊力哈木江．沙比提．apoE基因多态性与异常黑胆质型疾病的关系[J]．中华医学遗传学杂志，2003，20(6)：549-550
[100] MATTA, S. G., J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56:516-525
[101] Wilder R. Neuroendocrine-immune system interactions and auto immunity. Annu Rev Immuno 1, 1995,13:307-314
[102] SCHMIDT, E. D., A. W.J.W. JANSZEN, F. G. WOUTERLOOD et al. Interleukin-l-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J. Neurosci. 1995, 15:7417-7426
[103] ITO, Y., J. FUKATA, S. NAKAISHI, et al. Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 1990, 51: 637-641
[104] Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2):154
[105] SWEEP, C. G.J.F., M. J.M. VAN DER MEER, et al. Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1β infusion: in vivo and in vitro studies. Endocrinology 1992, 130: 1153-1164
[106] 阿吉．阿不力米提．玉素甫主编．维吾尔医学基础理论．卫生厅人民出版社，1988
[107] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]， 2003，34-38
[108] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，78-79
[109] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，93-94
[110] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，138-139
[111] Ebrahimi, BTucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 2004; 15:101 (12):2727-2736
[112] Anna CSISAR, Tamás SZENTES, Bea HARASZTI,et al.The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004; 10(2): 109-116
[113] Pfitzenmaier J, Vessella R, Higano CS, Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003 Mar 1; 97(5):1211-6
[114] Rutkowski P, Kaminska J, Kowalska M, et al. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer. 2002 Aug 1; 100(4):463-71
[115] Sephton S. Spiegel circadian disruptions in cancer: a neruo-endocrine-immune pathway from stress to disease[J]. Brain Behave Immune. 2003, 17(5): 321-328
[116] Touitou Y, Bogdan A,Levi F Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: Relationships with tumor marker antigens[J]. Br J Cancer, 1996, 74:1248-1252
[117] Price MA, Tennant CC, Butow PN, et al. The role of psychosocial factors in the development of breast carcinoma: Part Ⅱ. Life event stressors, social support, defense style, and emotional control and their interactions[J]. Cancer, 2001, 91(4):686-697
[118] Rowse GL,Weinberg J, Bellward GD, et al. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth[J]. Cancer Lett, 1992, 65:85-93
[119] BESEDOVSKY, H. O., AND A. DEL REY. Immune-neuroendocrine interactions: facts and hypotheses. Endocr. Rev. 1996, 17:64-102
[120] IGENT, D. A., J. E. BLALOCK. Interaction beteen neuroendocrine and immunesystems: common hormones and receptors. Immunol. Rev. 1987, 100:79-108
[121] DE SOUZA, E. B., E. L. WEBSTER, D. E. GRIGORIADIS, AND D. E. TRACEYCorticotropin-releasing factor (CRF) and interleukin-1 receptors in the brain-pituitary-immune axis. Psychopharmacol. Bull. 1991, 25:299-305
[122] PURBA, J. S., F. C. RAADSHEER, M. A. HOFMAN, R. RAVID, C. H. POLMAN, W. KAMPHORST, AND D. F. SWAAB. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology1995,62:62-70
[123] BLALOCK, J. E. The syntax of immune-neuroendocrine communication. Immunol. 1994, 15:504-511
[124] 哈木拉提．吾甫尔．异常黑胆质证载体动物模型的建立及其自然恢复反正．新疆医科大学学报．2006，29(10)：910-914
[125] 阿依努尔．卖提斯迪克，哈木拉提．吾甫尔．异常黑胆质证载体动物模型下丘脑-垂体-肾上腺轴组织形念学观察．新疆医科大学学报．2006，29(10)：914-916
[126] 王薇文，主编．实验肿瘤学基础．人民卫生出版社，1992：18-19
[127] 郭鹤，主编．人类疾病的动物模型．第一辑．人民卫生出版社，1990：34
[128] Pantellouris, E.M. Absence of thymus in a mouse mutant. Nature. 1968; 271:370-371
[129] 李敏明．我国建立的实验动物肿瘤模型．上海实验动物科学．1984，4(4)：247-258
[130] 杨斌．裸小鼠与人类肿瘤移植．肿瘤防治杂志．1985；12(1)：44-47
[131] 汪兼，主编．现代医学实验方法．人民卫生出版社．1998：104
[132] Foley, G.E.Droley, B.P. Sustained Propagation of Sarcoma 180 in Tissue Culture.Pro.Soc.Exper.Bio.Med. 1956, 92:347-352
[133] Caroline C.Beaufour, Nicolas Ballon.Effects of antidepressants in Operant Conflict.Procedure of anxiety in rat. Pharmacology Biochemistry and Behavior. 1999, 4(61):591-599
[134] Joao Palermo-Neto. Effects of physical and psychological stressor on behavior, macrophage activity, and Ehrlich tumor growth. Brain, Behavior and immunty, 2003
[135] 余慕贞，黄国平．小鼠S180核型的建立及其意义．实验生物学报．1988，1：88
[136] 侯子正．S180移植瘤在不同品系小鼠生长的观察．肿瘤临床．1984，4(11)：240
[137] Besedovskyho. Changes in blood hormones during the immune under sponse[J]. Proc Soc Exp Biot Med, 1988, 15(1):466-471
[138] Yoshida N, Ikemoto S, Narita K, et al: Interleukin-6, tumour necrosis factor alpha and interleukin-lbeta in patients with renal cell carcinoma. Br J Cancer. 2002; 86(9): 1396-1400
[139] Dunn AJ. Cytokinsasa bridage between immune and neuroendocrine system[J].Prog Neuroendocrine immunol, 1990, 3:26-34
[140] Blalock JE. A molecular basic for bidirectional communication between the immune and endocrine system[J]. Physiol Rev, 1989, 69(1):1-5
[141] Besedovsky HO, Sorkin E. Network of immune neuroendocrine interaction[J]. Clin Exp Immunol, 1991, 27:5-12
[142] BESEDOVSKY HA. DELREY, E. SORKIN, et al. Immunoregulatory feedback between interleukin- 1 and glucocorticoid hormones. Science. 1986; 233:652-654
[143] Foley, G E. Isolation and serial propagation of malignant and normal cells in semi-defined media origins of CCRF cells lines. Cancer Research. 1960, 20:930-938
[144] 施新秋，编著．医用实用动物学．陕西科技出版社．1989，243-245
[145] 张晓边．比较小鼠移植性肿瘤S180和S180A在抗癌药理中的作用．中国药理学会通讯．1995；12(3)：11-13
[146] 王秀芬．不同S180细胞株蛋白质特性的电泳及免疫组化研究得比较．实验动物科学与管理．2000；17(1)：7-9
[147] 高进，李敏明．中国人类免疫缺陷动物体内的模型建立及现存的问题．中华肿瘤杂志．1999；21(1)：69-72
[148] 顾文霞．小鼠瘤细胞免疫学的初步研究．生物化学杂志．1985；3(1)：65-71
[149] 金敬善，邓新荣，邹世洁．脾气虚证与神经分泌免疫网络相关性的研究．中国中医基础医学杂志，1997，3(3)：34-37
[150] BLALOCK, J. E., D. HARBUR-MCMENAMIN, E. M. SMITH. Peptide hormones shared by the neuroendocrine and immunologic systems. J. Immunol. 135, Suppl.: 1985, 858s-861s
[151] Sch PJ. Stress and cancer in: Cary L Cooper. Psychosocial Stress and Cancer. Jone Wiley & Sons Ltd, 1984
[152] ZHOU, D., A. W. KUSNECOV, M. R. SHURIN, M. DEPAOLI, AND B. RABIN. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 1993, 133: 2523-2530
[153] 王文芳，姚立人．应急对肿瘤转移的影响及免疫机制[J]．癌症，1992，11(2)：107-120
[154] 艾斯卡尔·依米提，哈木拉提·吾甫尔，布再娜甫·伊力哈木．维吾尔医成熟及清除剂诱导T淋巴瘤细胞凋亡的研究，中药药理与临 床．2000，2：36-38
[155] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木．维医成熟、清除剂诱导人Hela细胞凋亡时p53与bcl-2基因的表达．新疆医科大学学报．2000，1：57-60
[156] 哈木拉提，阿不都热依木，阿不都艾尼等．维吾尔医成熟剂和清除剂抗活性氧的作用研究．中国民族医药杂志．2000，3：54-56
[157] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木江·沙比提．异常黑胆质成熟剂与清除剂对人Hela细胞凋亡基因表达的影响．细胞与分子免疫学志．2001；2：112-114．
[158] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木江·沙比提等．维吾尔族异常黑胆质型患者基因多态性研究．中华医学遗传学杂志．2003；1(3)：540-550
[159] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，141-144
[160] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，166-170
[161] Hu J, Chen Z, Gorczynski CP, et al. Sleep-deprived mice show altered eytokine production manifest by perturbations in serum IL-lra, TNFa, and IL-6 levels. Brain Behav Immun. 2003 Dec; 17(6):498-504
[162] MATTA, S. G., J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1 β. Neuroendocrinology 1992, 56:516-525
[1] 顾宏涛．细胞防护剂WR-2721研究进展[J]．囡外医学放射医学核医学分册，2003，27：135-137
[2] 哈木拉提．吾甫尔．异常黑胆质成熟剂和清除剂体内外抗氧化功能的研究[M]．维吾尔医气质、体液论及其现代研究，2003，100-115
[3] 赵文仲，沈建良．甾体雌激素在放射损伤性造血重建中的作用机理[J]．中华放射医学与防护杂志，1991，11(1)：8
[4] 杨世海，尹春梅，缪双红．银耳多糖及其药理作用的研究进展[J]．中草药，1993，24(3)：153
[5] 梅其炳，陶静仪，张惠迪等．当归多糖对照射小鼠造血干细胞的影响[J]．中国药理学报，1988，9(3)：279
[6] Hari KUMAR.K.B, Sabu. M.C. Modulation of Haematopoetic System and Antioxidant Enzymes by Emblica officinal is gerent and its protective Role Against r-radiation induced damages in Mice[J]. Radiate Res, 2004, 45:549-555
[7] 哈木拉提．吾甫尔．异常黑胆质成熟剂和清除剂对DNA辐射损伤的保护作用研究[M]．维吾尔医气质、体液论及其现代研究，2003，122-124
[8] Bump, E.A. Brown.J.M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo (J). Pharmacologic.Ther. 1990, 47:117-120
[9] Tannehil, S.P. Metha, M.E Amifostine and radiation therapy: past, present and future. Semin[J]. Oncol. 1996, 28:8-69
[10] 徐冰心，肖成荣，郑思新等．辐射防护及研究进展[J]．中华放射医学与防护杂志，2002，22：64-69
[1] ADDISON, T. On the Constitutional and Local Effects of the Suprarenal Capsules. London: Highley, 1855.
[2] HENCH, P. S., E. C. KENDALL, C. H. SLOCUMB, AND H. F. POLLEY. The effect of a hormone of the adrenal cortex (17-hydroxycorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clinic Proe. 1949,24: 181-197.
[3] MCEWAN, B. S., C. A. BIRON, K. W. BRUNSON, et al. The role of adrenocortieoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Rev. 1997,23:79-133.
[4] BESEDOVSKY, H., E. SORKIN, M. KELLER, et al. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 1975, 150: 466-470.
[5] BESEDOVSKY, H. O., A. DEL REY, E. SORKIN. Lymphokine- containing supernatants from Con A-stimulated cells increase corticosterone blood levels. J. Immunol. 1981, 126: 385-387.
[6] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955.
[7] BESEDOVSKY, H., A. DEL REY, E. SORKIN, et al. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233: 652-654
[8] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955
[9] BRISTULF, J., A. SIMONCSITS, T. BARTFAI. Characterization of a neuronal interleukin-1 receptor and the corresponding mRNA in the mouse anterior pituitary cell line AtT-20. Neurosci. Lett. 1991, 128: 173-176
[10] ATKINS, E. Pathogenesis of fever. Physiol. Rev. 1986, 40: 580-646
[11] KLUGER, M. J. Fever: role of pyrogens and cryogens. Physiol. Rev. 1991,71:93-127
[12] BERKENBOSCH, F., D. E.C. DEGOEIJ, A. DEL REY, et al. Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. Neuroendocrinology 1989, 50: 570-576.
[13] BESEDOVSKY, H. O., A. DEL REY. Immune-neuroendocrine interactions: facts and hypotheses. Endocr. Rev. 1996, 17: 64-102
[14] KENT, S., J. L. BRET-DIBAT, K. W. KELLEY, et al. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci. Biobehav. Rev. 1996, 20: 171-175
[15] KRUEGER, J. M., AND J. A. MAJDE. Cytokines and sleep. Int. Arch. Allergy Immunol. 1995, 106: 97-100
[16] COHEN, M. C, AND S. COHEN. Cytokine function. A study in biological diversity. Am. J. Clin. Pathol. 1996, 105: 589-598
[17] PAUL, W. E.. Pleiotropy and redundancy: T-cell derived lymphokines in the immune response. Cell 1989, 57: 521-524
[18] KISHIMOTO, T., T. TAGA, AND S. AKIRA. Cytokine signal transduction. Cell 1994, 76: 253-262
[19] SATO, N., AND A. MIYAJIMA. Multimeric cytokine receptors: common versus specific functions. Curr. Opin. Cell Biol. 1994 ,6: 174-179
[20] OPP, M. R., AND J. M. KRUEGER. Anti-interleukin-1β reduces sleep and sleep rebound after sleep deprivation in rats. Am. J. Physiol. 266(Regulatory Integrative Comp. Physiol. 1994, 35: R688-R695
[21] CANNON, J. G, R. A. FIELDING, M. A. FIATARONE, et al. Increased interleukin-1 beta in human skeletal muscle after exercise. Am. J. Physiol. 257(Regulatory Integrative Comp. Physiol. 1989, 26: R451-R455
[22] CANNON, J. G, C. A. DINARELLO. Increased plasma interleukin-1 activity in women after ovulation. Science. 1985, 227: 1247-1249
[23] DINARELLO, C. A.The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163: 1177-1184
[24] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supresses' induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[25] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supress's induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[26] RIVIER, C., P. M. PLOTSKY. Mediation by corticotropin- releasing factor (CRF) of adenohypophysial hormone secretion. Annu. Rev. Physiol. 1986, 48: 475-494
[27] TURNBULL, A. V., AND C. RIVIER. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein and related peptides. Proc. Soc. Exp. Biol. Med. 1997,215: 1-10
[28] VALE, W., J. SPEISS, C. RIVIER,et al. Characterization of a 41-amino acid residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science .1981, 213: 1394-1397
[29] KELLER-WOOD, M. E., M. F. DALLMAN. Corticosteroid inhibition of ACTH secretion. Endocr. Rev. 1984, 5: 1-24
[30] MORGAN, J. I., AND T. CURRAN. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes FOS and jun. Annu. Rev. Neurosci. 1991, 14: 421-451
[31] BAN, E., L. SARLIEVE, F. HAOUR. Interleukin-1 binding sites on astrocytes. Neuroscience. 1993, 52: 725-733
[32] MATTA, S. G, K. M. LINNER, AND B. M. SHARP. Interleukin-1β and interleukin-1β stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology. 1993,57:14-22
[33] NAITO, Y., J. FUKATA, T. TOMINAGA, et al. Adrenocorticotropic hormone releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res. Commun. 1989, 164: 1262-1267
[34] SCHOTANUS, K., R. H. MELOEN, W. C. PUJIK, et al. Effects of monoclonal antibodies to specific epitopes of rat interleukin-1 beta (IL-1β) on IL-1β-induced ACTH corticosterone and IL-6 responses in rats. J. Neuroendocrinol. 1995, 7: 255-262
[35] SCHMIDT, E. D., A. W.J.W. JANSZEN, F. G. WOUTERLOOD, et al. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J. Neurosci. 1995, 15: 7417-7426
[36] NAITO, Y., J. FUKATA, S. NAKAISHI, et al. Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 1990, 51: 637-641
[37] SWEEP, C. G.J.F., M. J.M. VAN DER MEER, A. R.M.M. HERMUS, et al. Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1β infusion: in vivo and in vitro studies. Endocrinology 1992, 130: 1153-1164
[38] VAN DER MEER, M. J.M., C. G.J.F. SWEEP, G. J. PESMAN, et al. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine1996, 8: 910-919
[39] MATTA, S. G, J. WEATHERBEE, B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56: 516-525
[40] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, et al. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992,6:214-222
[41] CURTI, B. D., W. J. URBA, D. L. LONGO, et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996,19:142-148
[42] MASTORAKOS, G, G P. CHROUSOS, J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[43] NOLTEN, W. E., D. GOLDSTEIN, M. LINDSTROM, et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J. Interferon Res. 1993, 13: 349-357
[44] HERSEY, P, A. COATES, M. RALLINGS, et al. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanomas. J. Biol. Response Modif. 1986, 5: 236-249
[45] MASTORAKOS, G., G. P. CHROUSOS, J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[46] MASTORAKOS, G, J. S. WEBER, M.A. MAGIAKOU, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J. Clin. Endocrinol. Metab. 1994,79: 934-939
[47] MASTORAKOS, G, G. P. CHROUSOS, AND J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[48] DUNN, A. J., M. L. POWELL, C. MEITIN, et al. Virus infection as a stressor: influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol. Behav. 1989, 45: 591-594
[49] RIVIER, C. Effect of peripheral and central cytokines on the hypothalamo-pituitary-adrenal axis of the rat. Ann. NY Acad. Sci. 1993,697:97-105
[50] DUNN, A. J., S. L. VICKERS. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994,645: 103-112
[51] RUZEK, M. C, A. H. MILLER, S. M. OPAL, et al. Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J. Exp. Med. 1997, 185: 1185-1192
[52] TURNBULL, A. V., C. RIVIER. Intracereboventricular (icv) passive immunization I: the effect of icv administration of an antisera to tumor necrosis factor-α on the plasma ACTH response to lipopolysaccharide in rats. Endocrinology 1998, 139:119-127
[53] LUHESHI, G, A. J. MILLER, S. BROUWER, et al. Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am. J. Physiol. 270(Endocrinol. Metab. 1995 ,33: E91-E95
[54] SMITH, B. K., AND M. J. KLUGER. Human IL-1 receptor antagonist partially suppresses LPS fever but not plasma levels of IL-6 in Fisher rats. Am. J. Physiol. 263(Regulatory Integrative Comp. Physiol. 1992, 32: R653-R655
[55] COOPER, A. L., S. BROUWER, A. V. TURNBULL, et al. Tumor necrosis factor-alpha and fever after peripheral inflammation in the rat. Am. J.Physiol. 267(Regulatory Integrative Comp. Physiol. 1994, 36:R1431-R1436
[56] GERSHENWALD, J. E., Y. FONG, T. J. FAHEY, et al. Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc. Natl. Acad. Sci. USA 1990, 87: 4966-4970
[57] WUSTEMAN, M., D. G.D. WIGHT, M. ELIA. Protein metabolism after injury with turpentine: a rat model for clinical trauma. Am. J. Physiol. 259(Endocrinol. Metab. 1990, 22: E763-E769
[58] SMITH, M. A., S. MAKINO, S. Y. KIM, et al. Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 1995, 136: 3743-3750
[59] ZHOU, D., A. W. KUSNECOV, M. R. SHURIN, M. DEPAOLI, AND B. RABIN. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of the hypothalamo-pituitary-adrenal axis. Endocrinology,1993,133: 2523-2530
[60] SHIZUYA, K., T. KOMORI, R. FUJIWARA, et al. The influence of restraint stress on the exposure of mRNAs for IL-6 and the IL-6 receptor in the hypothalamus and midbrain of the rat. Life Sci. 1997,61:135-140
[61] HOPKINS, S. J., N. J. ROTHWELL. Cytokines and the nervous system I: expression and regulation. Trends Neurosci. 1995,18: 83-88
[62] SEI, Y, L. VITKOVIC, M. M. YOKOYAMA. Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Neuroimmunomodulation 1995, 2: 121-133
[63] FARRAR, W. L., P. L. KILIAN, M. R. RUFF, et al. Visualization and characterization of interleukin 1 receptors in brain. J. Immunol. 1987, 139:459-463
[64] TOMOZAWA, Y, T. INOUE, M. SATOH. Expression of type I interleukin-1 receptor mRNA and its regulation in cultured astrocytes. Neurosci. Lett. 1995, 195: 57-60
[65] TAISHI, P., S. BREDOW, N. GUHA-THAKURTA, F. O. OBAL, AND J. M. KRUEGER. Diurnal variations of interleukin-1β mRNA and β-actin mRNA in rat brain. J. Neuroimmunol. 1997, 75: 69-74
[66] HOPKINS, S. J., N. J. ROTHWELL. Cytokines and the nervous system I: expression and regulation. Trends Neurosci. 1995, 18: 83-88
[67] SCHOBITZ, B., E. R. DE KLOET, F. HOLSBOER. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog. Neurobiol. 1994, 44: 397-432
[68] MURAMAMI, N., J. FUKATA, T. TSUKADA.et al. Bacterial lipopolysaccharide-induced expression of interleukin-6 messenger ribonucleic acid in the rat hypothalamus, pituitary, adrenal gland, and spleen. Endocrinology 1993, 133: 2574-2578
[69] SWIERGIEL, A. H., A. J. DUNN, AND E. A. STONE. The role of cerebral noradrenergic systems in the fos response to interleukin-1. Brain Res. Bull. 1996,41:61-64
[70] NIIMI, M., M. SAT, Y. WADA, J. TAKAHARA, et al. Effect of central and continuous intravenous injection of interleukin-1β on brain c-fos expression in the rat: involvement of prostaglandins. Neuroimmunomodulation 1996, 3: 87-92
[71] ZELAZOWSKI, P., V. K. PATCHEV, E. B. ZELAZOWSKA, et al. Release of hypothalamic corticotropin-releasing hormone and arginine vasopressin by interleukin-1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res. 1993,631:22-26
[72] YASIN, S. A., A. COSTA, D. HUCKS, et al. Interleukin-induced vasopressin release is inhibited by L-arginine. Ann. NY Acad. Sci. 1993, 689: 693-695
[73] SAPOLSKY, R., C. RIVIER, G. YAMAMOTO, et al. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987, 238: 522-524
[74] VAN DER MEER, M. J.M, C. G.J. SWEEP, C. E.M. RIJNKELS, et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1β, TNFα and IL-6: a dose response study. J. Endocrinol. Invest. 1996, 19:175-182
[75] TAKAO, T., C. TOJO, T. NISHIOKA, et al. Reciprocal modulation of corticotropin-releasing factor and interleukin-1 receptors following ether-laparotomy stress in the mouse. Brain Res. 1994, 660: 170-174
[76] TAKAO, T., C. TOJO, T. NISHIOKA, et al. Stress-induced upregulation of pituitary interleukin-1 receptors is mediated by corticotropin-releasing factor. Life Sci. 1996, 59:165-168
[77] AKITA, S., J. WEBSTER, S. G. REN, et al. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J. Clin. Invest. 1995, 95: 1288-1298
[78] ARZT, E., G. STEIZER, U. RENNER, et al. Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J. Clin. Invest. 1992, 90: 1944-1951
[79] BERNHAGEN, J., T. CALANDRA, R. A. MITCHELL, et al. Macrohpage migration inhibitory factor (MIF) is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 1993,365:756-759
[80] BUCALA, R. Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shock. Immunol. Lett. 1994,43: 23-26
[81] CALANDRA, T., J. BERHAGEN, C. N. METZ, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995,377:68-71
[82] TURNBULL, A.V., C. R1VIER. Cytokines within the neuroendocrine system. Curr. Opin. Endocrinol. Diabetes 1996, 3: 149-156
[83] SPANGELO, B. L., A. M. JUDD, P. C. ISAKSON, et al. Interleukin-1 stimulates interleukin-6 release from rat anterior pitutary cells in vitro. Endocrinology 1991, 128: 2685-2692
[84] BILEZIKJIAN, L. M., A. L. BLOUNT, C. A. CAMPEN, et al. Activin-A inhibits proopiomelanocortin messenger RNA accumulation and adrenocorticotropin secretion of AtT20 cells. Mol. Endocrinol. 1991, 5: 1389-1395
[85] DE SOUZA, E. B., E. L. WEBSTER, D. E. GRIGORIADIS,et al. Corticotropin-releasing factor (CRF) and interleukin-1 receptors in the brain-pituitary-immune axis. Psychopharmacol. Bull. 1991, 25: 299-305.
[86] WEBSTER, E. L., D. E. TRACEY, E. B. DE SOUZA. Upregulation of interleukin-1 receptors in mouse AtT-20 pituitary cells following treatment with corticotropin-releasing factor. Endocrinology 1991, 129: 2796-2798
[87] CUNNINGHAM, E. T. JR., E.WADA, D.B.CARTER, et al. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J. Neurosci. 1992, 12:1101-1114
[88] PATH, G., S. R. BORNSTEIN. Interleukin-6 and interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82: 2343-2349.
[89] SCHULTZBERG, M., C. ANDERSSON, A. UNDEN, et al. Interleukin-1 in adrenal chromaffin cells. Neuroscience 1989, 30: 805-810
[90] CONTI, B., J. W. JAHNG, C. TINTI, et al. Induction of interferon-gamma inducing factor in the adrenal cortex. J. Biol. Chem. 1997, 272: 2035-2037
[91] SCHOBITZ, B., M. VAN DOBBELSTEEN, F. HOLSBOER,et al. Regulation of interleukin-6 gene expression in rat. Endocrinology 1993, 132: 1569-1576
[92] MURAMAMI, N., J. FUKATA, T. TSUKADA, et al. Bacterial lipopolysaccharide-induced expression of interleukin-6 messenger ribonucleic acid in the rat hypothalamus, pituitary, adrenal gland, and spleen. Endocrinology 1993, 133: 2574-2578
[93] GWOSDOW, A. R., M. S.A. KUMAR, H. H. BODE. Interleukin-1 stimulation of the hypothalamo-pituitary-adrenal axis. Am. J. Physiol. 258(Endocrinol. Metab. 1990, 21: E65-E70
[94] DARLING, G, D. S. GOLDSTEIN, R. STULL, et al. Tumor necrosis factor: immune endocrine interaction. Surgery. 1989,106: 1155-1160
[95] PATH, G., AND S. R. BORNSTEIN. Interleukin-6 and interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82: 2343-2349
[96] GISSLINGER, H., T. SVOBODA, M. CLODI, et al. Interferon-alpha stimulates the hypothalamo-pituitary axis in vivo and in vitro. Neuroendocrinology 1993, 57: 489-495
[97] VAN DER MEER, M, C. G.J. SWEEP, C. E.M. RIJNKELS, et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1β, TNFα and IL-6: a dose response study. J. Endocrinol. Invest. 1996,19:175-182
[98] SARLIS, N. J., A. STEPHANOU, R. A. KNIGHT, et al. Effects of glucocorticoids and chronic inflammatory stress upon anterior pituitary interleukin-6 mRNA in the rat. Br. J. Rheumatol. 1993, 32: 653-657
[99] SPRENGER, H., C. JACOBS, M. NAIN, et al. Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running. Clin. Immunol. Immunopathol. 1992, 63: 188-195
[100] ZIELENIEWSKI, W., J. ZIELENIEWSKI, H. STEPIEN. Effect of Interleukin-1α, IL-1β and IL-1 receptor antibody on the proliferation and steroidogenesis of regenerating rat adrenal cortex. Exp. Clin. Endocrinol. Diabetes 1995, 103: 373-377
[101] Gaillard RC. Intreactions between the immune and neuroendocrine system: clinical implications. J Scol Biol. 2003:197(2):89-95
[102] ThyagaRajan S, Felten DL.Modulation of neuroendocrine-immune signaling by L-deprenyl and L-desmethyLdeprenyl in aging and mammary cancer.Mdch Ageing Dev. 2002 Apr 30:123(8): 1065-79
[103] John CD, Buckingham JC. Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Curr Opin Pharmacol. 2003 Feb;3(1):78-84
[104] Corcos M,Guilbaud O,Paterniti S.Moussa M,Chaouat G,Consoli SM, Jeammet P.Involvement of cytokines in eating disorders: a critical review of the human literature. Psychoneuroendocrinology. 2003 Apr; 28(3):229-49
[105] Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002; 20:125-63. Epub 2001 Oct 04
[106] Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic- pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2):154
[1] SELLMEYER, D. E., and C. GRUNFIELD. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr. Rev. 1996, 17:518-532
[2] JAFFE, H. L. The influence of the suprarenal gland on the thymus. III. Stimulation of the growth of the thymus gland following double suprarenalectomy in young rats. J. Exp. Med. 1924, 40: 753-760
[3] ADDISON, T. On the Constitutional and Local Effects of the Suprarenal Capsules. London: Highley, 1855
[4] HENCH, P. S., E. C. KENDALL, C. H. SLOCUMB, AND H. F. POLLEY. The effect of a hormone of the adrenal cortex (17-hydroxycorticosterone: compound E) and of pituitary adrenocorticotropic
[5] SELYE, H. Thymus and adrenals in the response of the organism to injuries and intoxications. Br. J. Exp. Pathol. 1936, 17: 234-248
[6] MUNCK, A., P. M. GUYRE, AND N. J. HOLBROOK. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 1984, 5: 25-44
[7] DEL REY, A., H. BESEDOVSKY, AND E. SORKIN. Endogenous blood levels of corticosterone control the immunologic cell mass and B cell activity in mice. J. Immunol. 1984, 133: 572-575
[8] BESEDOVSKY, H., E. SORKIN, M. KELLER, AND J. MULLER. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 1975, 150: 466-470
[9] BESEDOVSKY, H. O., A. DEL REY, AND E. SORKIN. Lymphokine-containing supernatants from Con A-stimulated cells increase corticosterone blood levels. J. Immunol. 1981, 126: 385-387
[10] MCEWAN, B. S, BIRON, K. W. BRUNSON, K. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Rev. 1997,23:79-133
[11] SMITH, E. M, AND J. E. BLALOCK. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. USA .1981,78:7530-7534
[12] BESEDOVSKY, H., A. DEL REY, E. SORKIN, AND C. A. DINARELLO. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233: 652-654
[13] HEALY, D. L., G. D. HODGEN, H. M. SCHULTE, et al, ethymus-adrenal connection: thymosin has corticotropin-releasing activity in primates. Science 1983, 222: 1353-1355
[14] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955
[15] BRODISH, A. Extra-CNS corticotropin-releasing factors. Ann. NY Acad. Sci. 1977, 297: 420-435
[16] BRODISH, A.. Tissue corticotropin releasing factors. Federation Proc. 1977,36:2088-2093
[17] LYMANGROVER, J. R., AND A. BRODISH. Tissue CRF: an extrahypothalamic corticotropihin releasing factor (CRF) in peripheral blood of stressed rats. Neuroendocrinology 1973, 12: 225-235
[18] WOLOSKI, B.M.R.N. J., E.M. SMITH, et al. Corticotropin-releasing activity of monokines. Science. 1985,230: 1035-1037
[19] BLALOCK, J. E. The syntax of immune-neuroendocrine communication. Immunol. Today. 1994, 15: 504-511
[20] BLALOCK, J. E., D. HARBUR-MCMENAMIN, AND E. M. SMITH. Peptide hormones shared by the neuroendocrine and immunologic systems. J. Immunol. 1985, 135, Suppl.: 858s-861s
[21] DUNN, A. J., M. L. POWELL, AND J. M. GASKIN. Virus-induced increases in plasma corticosterone. Science. 1987, 238: 1423-1424
[22] DUNN, A. J., AND S. L. VICKERS. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994, 645: 103-112
[23] SMITH, E. M., AND J. E. BLALOCK. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. USA.1981,78:7530-7534
[24] SMITH, E. M., M. PHAN, T. E. KRUGER, D. H. COPPENHAVER, AND J. E. BLALOCK. Human lymphocyte production of immunoreactive thyrotropin. Proc. Natl. Acad. Sci. USA. 1983, 80: 6010-6013
[25] WEIGENT, D. A., AND J. E. BLALOCK. Interaction beteen neuroendocrine and immune systems: common hormones and receptors. Immunol. Rev. 1987, 100: 79-108
[26] WEIGENT, D. A., AND J. E. BLALOCK. Production of peptide hormones and neurotransmitters by the immune system. Chem. Immunol. 1997,69: 1-30
[27] OLSEN, N. J., W. E. NICHOLSON, C. R. DEBOLD, et al. Lymphocyte-derived adrenocorticotropin is insufficient to stimulate adrenal steroidogenesis in hypophysectomized rats. Endocrinology 1992,130: 2113-2119
[28] COHEN, M. C., AND S. COHEN. Cytokine function. A study in biological diversity. Am. J. Clin. Pathol. 1996, 105: 589-598
[29] PAUL, W. E.. Pleiotropy and redundancy: T-cell derived lymphokines in the immune response. Cell 1989, 57: 521-524
[30] ISHIMOTO, T., T. TAGA, AND S. AKIRA. Cytokine signal transduction. Cell 1994,76: 253-262
[31] SATO, N., AND A. MIYAJIMA. Multimeric cytokine receptors: common versus specific functions. Curr. Opin. Cell Biol. 1994, 6: 174-179
[32] OPP, M. R., AND J. M. KRUEGER. Anti-interleukin-1β reduces sleep and sleep rebound after sleep deprivation in rats. Am. J. Physiol. 266(Regulatory Integrative Comp. Physiol. 1994, 35: R688-R695
[33] CANNON, J. G., R. A. FIELDING, M. A. FIATARONE, S. F. ORENCOLE, C. A. DINARELLO, AND W. J. EVANS. Increased interleukin-1 beta in human skeletal muscle after exercise. Am. J. Physiol. 257(Regulatory Integrative Comp. Physiol. 1989, 26: R451-R455
[34] CANNON, J. G, AND C. A. DINARELLO. Increased plasma interleukin-1 activity in women after ovulation. Science. 1985, 227: 1247-1249
[35] DINARELLO, C. A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163: 1177-1184
[36] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supresses' induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[37] ORDAN, M., I. G. OTTERNESS, R. NG, A. GESSNER, M. ROLLINGHOFF, AND H. U. BEUSCHER. Neutralization of endogenous IL-6 supress's induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[38] VAN DER MEER, M. J.M., C. G.J.F. SWEEP, et al. HERMUS. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine. 1996,8:910-919
[39] MATTA, S. G, J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56: 516-525
[40] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, A. J. CHOVER-GONZALEZ, AND S. L. LIGHTMAN. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992, 6:214-222
[41] CURTI, B. D., W. J. URBA, D. L. LONGO,et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996, 19: 142-148
[42] MASTORAKOS, G, G. P. CHROUSOS, AND J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary- adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993 , 77: 1690-1694
[43] NOLTEN, W. E., D. GOLDSTEIN, M. LINDSTROM,et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J. Interferon Res. 1993, 13: 349-357
[44] HERSEY, P., A. COATES, M. RALLINGS,et al. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanomas. J. Biol. Response Modif. 1986, 5: 236-249
[2] 孙燕．实用肿瘤内科学．北京：人民卫生出版社，1999．161-165
[3] 顾健人，杨胜利．要用系统性疾病的观念重新认识癌症．中华医学杂志．2005，85(8)：505-507
[4] Besedovsky H, et al. Network of immune-neuroendocrine interactions[J]. Clin Exp Immunol. 1977, 27:1
[5] BLALOCK, J. E. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol. Rev. 1989, 69:1-32
[6] SMITH, M, A, S. MAKINO, S. Y. KIM, AND R. KVETNANSKY. Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 1995, 136:3743-3750
[7] WEIGENT, D. A., J. E. BLALOCK. Production of peptide hormones and neurotransmitters by the immune system. Chem. Immunol. 1997, 69:1-30
[8] OTTAVIANI, E., E. CASELGRANDI, F. PETRAGLIA, AND C. FRANCESCHI. Stress response in the freshwater snail Planobarius corneus (L.) (gastropoda, pulmonata): interaction between CRF, ACTH, and biogenic amines. Gen. Comp. Endocrinol. 1992, 87:354-360
[9] Rosch P J. Stress and cancer. In: Cary L Cooper. Psychosocial Stress and Cancer. Jone Wiley & Sons L td, 1984
[10] Bodey B, Siegel SE. Mechanisms and markers of carcinogenesis and neoplastic progression[J]. Expert Opin Ther, 2005, 5(10): 1371-32
[11] Price MA, Tennant CC, Buttow PN, et al. The role of psychosocial factors in the development of breast carcinoma: Part II. Life event stressor. Social support, defense style , and emotional control and their interactions [J]. Cancer, 2001, 91(4): 686-697
[12] Prolo P. Neuroendocrien -immune Surveillance of Osteosarcoma; Emerging Hypothesis [J]. J Dent Res, 2003, 82(6): 417-21
[13] Rowse GL, Weiunberg J, Bellward GD, et al. Endocrine medication of psychosocial stressor effects on mouse mammary tumor growth [J]. Cancer Lett, 1992, 65; 85-93
[14] Lonitier P, Wildrick DM, Boman BM. The effects of steroids hormones on a human colon cancer line in vitro [J]. Anticancancer Res, 1992, 12: 1327-30
[15] Snoussi K, Strosberg AD, Ben Ahmed S, et al. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1 alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw. 2005; 16(4):253-260
[16] Crippa S, Mussi C, Angelini C, et al. Alteration of hypothalamus-pituitary-adrenal gland axis in colorectal cancer patients. Preliminary report. Minerva Chir. 2003 Aug; 58(4): 581-585
[17] Mazzoccoli G, Carughi S, De Cata A, et al. Neuroendocrine alterations in lung cancer patients. Neuro Endocrinol Lett. 2003 Feb-Apr;24(1-2):77-82
[18] Rutkowski P, Kaminska J, Kowalska M, et al. Cytokines serum levels in softtissure sarcoma patients: correlations with clincio-pathological features and prognosis. Int J Cancer. 2002 Aug1; 100(4):463-71
[19] Lee E, Shin YJ, Chong YH. Mechanisms involved in p rostaglandin E2-mediated neurop rotection against TNF-alpha: possible involvement of multip le signal transduction and beta-catenin /T-cell factor. J Immunol, 2004, 155: 21-31
[20] Gruber2Olip iz M, Stevenson R, Olip iz W, et al. Transcriptional pattern analysis of adrenergic immunoregulation in mice. Twelve hours norepinephrine treatment alters the expression of a set of genes involved in monocyte activation and leukocyte trafficking. J Immunol, 2004, 155: 136-142
[21] Nave H, Bedoui S, Moenter F, et al. Reduced tissue immigration of monocytes by neuropep tide Y during endotoxemia is associated with Y-receptor activation. J Neuroimmunol, 2004, 155: 1212
[22] MORGAN, J. I., AND T. CURRAN. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 1991,14: 421-451
[23] RIVIER.C, AND W. VALE. Interaction of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on ACTH secretion in vivo. Endocrinology .1983; 113: 939-942
[24] SAWCHENKO, P. E., L. W. SWANSON, AND W. W. VALE. Co-expression of CRF-and vasopressin-immunoreactivity in parvocellular neurosecretory neurons in the adrenalectomized rat. Proc. Natl. Acad. Sci. USA.1984; 81: 1883-1887
[25] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, A. J. CHOVER-GONZALEZ, AND S. L. LIGHTMAN. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992; 6: 214-222
[26] CURTI, B. D., W. J. URBA, D. L. LONGO, et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996; 19:142-148
[27] KOIV, L., E. MERISALU, K. ZILMER, et al. Changes of sympatho-adrenal and hypothalamo-pituitary-adrenocortical system in patients with head injury. Acta Neurol. Scand. 1997; 96: 52-58
[28] FASSBENDER, K., R. SCHMIDT, R. MOSSNER, et al. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 1994;25:1105-1108
[29] HARBUZ, M. S., G. L. CONDE, O. MARTI, et al. The hypothalamic-pituitary-adrenal axis in autoimmunity. Ann. NY Acad. Sci. 1997;823:214-224
[30] LEMAY, L. G., A. J. VANDER, M. J. KLUGER. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol. Behav. 1990;47:957-961
[31] MEKAOUCHE, M., L. GIVALOIS, G. BARBANEL, et al. Chronic restraint enhances interleukin-l-beta release in the basal state and after an endotoxin challenge, independently of adrenocorticotropin and corticosterone release. Neuroimmunomo-dulation 1994; 1: 292-299
[32] Haddad J J, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2): 154
[33] 易沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册，第一册．乌鲁木齐：新疆人民出版社．1988，第一版
[34] 哈木拉提·吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，51-52
[35] 哈木拉提·吾甫尔．维吾尔医气质、体液论及其现代研究[M]．2003，131-133
[36] 努尔买买提，哈木拉提·吾甫尔等．异常黑胆质成熟剂和清除剂对小鼠神内分泌免疫网络的的调节作用研究[C]．维吾尔医药及其他传统医学研究与应用；乌鲁木齐：新疆人民卫生出版社，2003年，11-12
[37] 易沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册，第六册．乌鲁木齐：新疆科技卫生出版社．1995，第一版
[38] Greer S. Psychoneuroimmunology: interaction between the nervous system and the immune system. Lancet, 1995, 345(8942): 99-103
[39] Kiecolt Glaser JK, Glaser R. Psychoneuroimmunology and cancer: factor and fiction. Eur, Cancer. 1999, 36(11): 1603-1607
[40] SabbioniM. Cancer and stress: A possible role for psychoneuroimmunoloy in cancer research in: C L Cooper, M Watson. Cancer and Stress: Psycholoical, Biological and Cop in. Studies. JohnW iley & Sons L td, 1991
[41] Ippoliti F, N atalia SM, PozziV, et- al. Psycho logical behavior and immunodep ression in women with breast cancer, Congress on Brain and Immunity. Acta- N euro lo.ica, 1991, 13 (5): 483-490
[42] De BrabanderB, Haeseleer F D, De BrabanderM, et- al. The protective effect of behavioral activation on the growth of a syngeneic tumo r and mortality in socially stressed mice. European Journal of Psychiatry, 1989, 3(4): 238-244
[43] Ben Eliyahu S, Yirm iya R, L iebesk J C, et- al. Stress increase metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. Brain, Behavior and Immunity, 1991, 5 (2):193-205
[44] A der R, Cohen N. P sychoneuroimmunology: Conditionin and stress. Annu. Rev. P sycho 1, 1993, 44:53-85
[45] 潘菊芬．神经内分泌与免疫系统[M]．见：张殿明，徐隆绍主编．神经内分泌学．第1版．北京：中国医药科技出版社，1991．349-355
[46] Esquifino A I, Chacon F, Cano P, et al. Twenty2four2hour rhythms of mitogenic responses, lymphocyte subset populations and amino acid content in submaxillary lymph nodes of growingmale rats subjected to calorie restriction. Immunol, 2004, 156: 66-73
[47] Wilder R. Neuroendocrine-immune system interactions and auto immunity. Annu Rev Immunol, 1995, 13:307-312
[48] Cullinan WE, Herman JP, Watson SJ. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis [J]. J Comp Neurol,1993, 332 :1-20
[49] Lechin F, Van der Dijis B, Vitelli F G, et- al. Psychoneuro-endocrineological and immunological parameters in cancer patients: Involovement of stress and depression. Psychoneuroendocrinology, 1990, 15(5-6):435-451
[50] Berghella AM, Pellegrini P, Del Beato T et al.: The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 toTH2 and back. Cancer Immunol Immunotherapy. 1998, 45: 241-249
[51] Dinarello CA. Biologic basis for Interleukin 1 in disease. Blood, 1996, 87:2095-2147
[52] VAN DER MEER, SWEEP, G. J. PESMAN, F. J.H.et al. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine 1996, 8:910-919
[53] MATTA, S. G, K. M. LINNER, AND B. M. SHARP. Interleukin-1β and interleukin-1β stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology 1993.57:14-22
[54] NAITO, Y., J. FUKATA, T. TOMINAGA, et al. Adrenocorticotropic hormone releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res. Commun. 1989,164:1262-1267
[55] 朱晓琴，李正莉，朱长庚．IL-1α或IL-6对大脑皮质星形胶质细胞细胞周期的影响[J]．神经解剖学杂志．2005，21(3)：313-316
[56] Anna CSISZAR, Tamás SZENTES, Bea HARASZTI,et al.The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004, 10(2):109-116
[57] Ogata A, Nishimoto N, Yoshizaki K. Advances in interleukin-6 therapy[J]. Rinsho Byori, 1999, 47 (4):321-326
[58] Nakashima K, Taga T. Gpl30 and the IL26 family of cytokines: signaling mechanisms and thrombopoietic activities[J].1 Semin Hematol, 1998, 35(3):2102-2211
[59] Villunger A, Egle A, Kos M, et al. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies[J]. Int J Cancer, 1996, 65(4):498-505
[60] Giometto B, Bozza F, Faresin F, et al. Immune infiltrates and cytokines in gliomas[J]. Acta Neurochir Wien, 1996, 138(1): 502-561
[61] Galvani V, Pret nar H K, Rup reht R R, et al. Soluble tumor necrosis factor receptor I (s TNFRI) as a prognostic f act or in melanoma patients in Slovene population[J]. Pf lugers Arch, 2000; 440 (5 Suppl):R61-63
[62] Libura J, Bet tens F, Radkowski A, et al. Polymorp hictumor necrosis f acter microsatellite TNFα 4 is associated wit h resistance of Hodgkin lymphoma t o chemotherapy and wit h relapses after therapy[J]. Anticancer Res, 2002, 22(2A):921-926
[63] James F. Holland, Emil Frei Ⅲ, Robert C. Bast. Cancer Medicine (Sth edition). Jr.Willian & wilkins, 2000
[64] Li J, Kelsey S M, Grahn M F, et al. Increased activity andsensitivity of mitochondrial respi rat oryenzymes t o tumor necrosis facter -α mediated inhibition is associated wit h increased cytotoxicity in drug resistant leukemic cell lines[J]. Blood, 1996,87(6):2401-2410
[65] Stein U, Walt her W, Laurencot C M, et al. Tumor necrosis facter alpha and expression of the multidrug resistance associated genes L RP and MRP[J]. J Natl Cancer Inst, 1997, 89(11):807-813
[66] 粟毅，吴亚梅．肿瘤坏死因子与白细胞介素2协同抑制肺腺癌细胞的研究．癌症．2000，19(8)：779-781
[67] W u S, Boyer CM, W h itaker RS, et al. Tumo r necro sis facto r Aas an autocrine and paracrine grow the factor for ovarianancer: Monok ine induct ion of tumor cell pro liferation and tumor necrosis factor A expression. Cancer Res, 1993; 53:1939
[68] Tamás SZENTES, Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2005; 11(2):124-130
[69] Takagi K, Tomita K, Fukushima, et al: Endogenous TNF inducibility and prognosis of colorectal cancer. Anticancer Res. 1998, 18:4141-4146
[70] Anna CSISZAR, Tamás SZENTES, Bea HARASZTI, et al. The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004; 10(2):109-116
[71] 汤钊主编，现代肿瘤学[M]．上海：上海医科大学出版社，1993，6：121-139
[72] 吕先科，玉寒冰，霍晓君，等．肺癌患者血清免疫抑制酸性蛋白及T细胞亚群联合检测的意义[J]．上海免疫学杂志，1999，19(3)：177
[73] 秦建国，韩本立，潘世春．原发性肝癌患者T淋巴细胞亚群及功能 变化在肿瘤复发中的临床意义[J]．中华实验外科杂志，1998，15(1)：11
[74] 王毅鑫，阮灿平，李莉，等．胃癌患者手术前后T细胞及其活化抗原表达的变化与临床意义[J]．上海免疫学杂志，1998，18(4)：228
[75] 程邦昌，陈克能，梅强，等．食管癌患者外周血T淋巴细胞亚群、肿瘤坏死因子的改变及其相关因素研究[J]．中华实验外科杂志，1998，19(3)：226
[76] Lin Z, Madras BK. Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol. 2006; 1(75):327-71
[77] Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005 Dec 20; 7(4):E847-51
[78] 张锦培，黄兴兵，关念红等．广泛性焦虑症与抑郁症棉衣、内分泌及单胺递质的对照研究[J]．中华精神科杂志．2004；37(4)：211-214
[79] Mazzoccoli G, Grilli M, Carughi S,et al. Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol, 2003; 16(2):167-174
[80] 李广太．妇科肿瘤患者外周血淋巴细胞亚群研究．中国肿瘤临床，1996，23(7)：505
[81] Rotstein. Int J Radiat Oncol Biol Phys. 1985; 11:921
[82] Shunjun, Yang. Radiology. 1988. 168:537
[83] Gregory T Wolf. Arch Otolaryngol. 1985; 111:716
[84] 周决，曹世龙．放疗后机体免疫功能改变初探[J]．上海面医学杂志．1996；11(1)：22-24
[85] Carleton C Stewant. Int J Radiat Oncol Biol Phys. 1988; 55:77
[86] 杜鹃，何执鼎．恶性肿瘤患者及化疗后外周血T淋巴细胞亚群的检测[J]．中国医师杂志，2003，5(4)：540-541
[87] 汤钊猷主编．现代肿瘤学[M]．上海医科大学出版社，1993，6：121-131
[88] 施靖华，陈腾，陈兆瑞．手术及化疗对胃癌患者免疫功能的影响[J]．第二军医大学学报，1995，16(5)：454-457
[89] 梁靖，李艳，刘晓玲等．化疗对结肠癌患者Th1和Th2类细胞因子表达的影响及意义．中国肿瘤临床．2006；33(6)：916-919
[90] 姚树坤，李洪祥，李星涛，等．恶性肿瘤患者化疗前后细胞免疫功能的监测[J]．中华物理医学杂志，1995，17(2)：84-861
[91] Nlulgl Mazzoccoll, Stefano Carughl, Angelo De Cata, et al. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit, 2005; 11(6): CR284-288
[92] Mussi C, Angelini C, Crippa S. Alteration of hypothalamus-pituitary-adrenal glands axis in colorectal cancer patients. Hepatogastroenterology. 2003; 50 Suppl 2: ccxxviii-ccxxxi
[93] Giovanni Mantovani, Clelia Madeddu, Antonio Macciò, et al.Cancer-Related Anorexia/Cachexia Syndrome and Oxidative Stress: An Innovative Approach beyond Current Treatment. Cancer Epidemiology Biomarkers & Prevention 2004; 13:1651-1659
[94] Crippa S, Mussi C, Angelini C, et al. Alteration of hypothalamus-pituitary-adrenal gland axis in colorectal cancer patients. Preliminary report. Minerva Chir. 2003 Aug; 58(4):581-585
[95] 伊沙克江．马合穆德，主编．中国医学百科全书维吾尔医学分册M]，第一册。乌鲁木齐：新疆人民卫生出版社．1988．第一版
[96] 买买提明．沙比尔．维吾尔医学诊断学[M]．乌鲁木齐：新疆科技卫生出版社，1993
[97] OTTAVIANI, E., AND C. FRANCHESCHI. The invertebrate phagocytic immunocyte: clues to a common evolution of immune and neuroendocrine systems. Immunol. Today 1997, 18:169-174
[98] Wang D. RusseU J,Xu H. Deregulated expreeon of DPI induces epidermis proliferation and enhances in skin carcinoma. JMolCarcinog. 2001, 31(2): 90-100
[99] 哈木拉提．吾甫尔，艾斯卡尔．依米提，伊力哈木江．沙比提．apoE基因多态性与异常黑胆质型疾病的关系[J]．中华医学遗传学杂志，2003，20(6)：549-550
[100] MATTA, S. G., J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56:516-525
[101] Wilder R. Neuroendocrine-immune system interactions and auto immunity. Annu Rev Immuno 1, 1995,13:307-314
[102] SCHMIDT, E. D., A. W.J.W. JANSZEN, F. G. WOUTERLOOD et al. Interleukin-l-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J. Neurosci. 1995, 15:7417-7426
[103] ITO, Y., J. FUKATA, S. NAKAISHI, et al. Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 1990, 51: 637-641
[104] Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2):154
[105] SWEEP, C. G.J.F., M. J.M. VAN DER MEER, et al. Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1β infusion: in vivo and in vitro studies. Endocrinology 1992, 130: 1153-1164
[106] 阿吉．阿不力米提．玉素甫主编．维吾尔医学基础理论．卫生厅人民出版社，1988
[107] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]， 2003，34-38
[108] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，78-79
[109] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，93-94
[110] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，138-139
[111] Ebrahimi, BTucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 2004; 15:101 (12):2727-2736
[112] Anna CSISAR, Tamás SZENTES, Bea HARASZTI,et al.The Pattern of Cytokine Gene Expression in Human Colorectal Carcinoma. Pathology Oncology Research, 2004; 10(2): 109-116
[113] Pfitzenmaier J, Vessella R, Higano CS, Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003 Mar 1; 97(5):1211-6
[114] Rutkowski P, Kaminska J, Kowalska M, et al. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer. 2002 Aug 1; 100(4):463-71
[115] Sephton S. Spiegel circadian disruptions in cancer: a neruo-endocrine-immune pathway from stress to disease[J]. Brain Behave Immune. 2003, 17(5): 321-328
[116] Touitou Y, Bogdan A,Levi F Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: Relationships with tumor marker antigens[J]. Br J Cancer, 1996, 74:1248-1252
[117] Price MA, Tennant CC, Butow PN, et al. The role of psychosocial factors in the development of breast carcinoma: Part Ⅱ. Life event stressors, social support, defense style, and emotional control and their interactions[J]. Cancer, 2001, 91(4):686-697
[118] Rowse GL,Weinberg J, Bellward GD, et al. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth[J]. Cancer Lett, 1992, 65:85-93
[119] BESEDOVSKY, H. O., AND A. DEL REY. Immune-neuroendocrine interactions: facts and hypotheses. Endocr. Rev. 1996, 17:64-102
[120] IGENT, D. A., J. E. BLALOCK. Interaction beteen neuroendocrine and immunesystems: common hormones and receptors. Immunol. Rev. 1987, 100:79-108
[121] DE SOUZA, E. B., E. L. WEBSTER, D. E. GRIGORIADIS, AND D. E. TRACEYCorticotropin-releasing factor (CRF) and interleukin-1 receptors in the brain-pituitary-immune axis. Psychopharmacol. Bull. 1991, 25:299-305
[122] PURBA, J. S., F. C. RAADSHEER, M. A. HOFMAN, R. RAVID, C. H. POLMAN, W. KAMPHORST, AND D. F. SWAAB. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology1995,62:62-70
[123] BLALOCK, J. E. The syntax of immune-neuroendocrine communication. Immunol. 1994, 15:504-511
[124] 哈木拉提．吾甫尔．异常黑胆质证载体动物模型的建立及其自然恢复反正．新疆医科大学学报．2006，29(10)：910-914
[125] 阿依努尔．卖提斯迪克，哈木拉提．吾甫尔．异常黑胆质证载体动物模型下丘脑-垂体-肾上腺轴组织形念学观察．新疆医科大学学报．2006，29(10)：914-916
[126] 王薇文，主编．实验肿瘤学基础．人民卫生出版社，1992：18-19
[127] 郭鹤，主编．人类疾病的动物模型．第一辑．人民卫生出版社，1990：34
[128] Pantellouris, E.M. Absence of thymus in a mouse mutant. Nature. 1968; 271:370-371
[129] 李敏明．我国建立的实验动物肿瘤模型．上海实验动物科学．1984，4(4)：247-258
[130] 杨斌．裸小鼠与人类肿瘤移植．肿瘤防治杂志．1985；12(1)：44-47
[131] 汪兼，主编．现代医学实验方法．人民卫生出版社．1998：104
[132] Foley, G.E.Droley, B.P. Sustained Propagation of Sarcoma 180 in Tissue Culture.Pro.Soc.Exper.Bio.Med. 1956, 92:347-352
[133] Caroline C.Beaufour, Nicolas Ballon.Effects of antidepressants in Operant Conflict.Procedure of anxiety in rat. Pharmacology Biochemistry and Behavior. 1999, 4(61):591-599
[134] Joao Palermo-Neto. Effects of physical and psychological stressor on behavior, macrophage activity, and Ehrlich tumor growth. Brain, Behavior and immunty, 2003
[135] 余慕贞，黄国平．小鼠S180核型的建立及其意义．实验生物学报．1988，1：88
[136] 侯子正．S180移植瘤在不同品系小鼠生长的观察．肿瘤临床．1984，4(11)：240
[137] Besedovskyho. Changes in blood hormones during the immune under sponse[J]. Proc Soc Exp Biot Med, 1988, 15(1):466-471
[138] Yoshida N, Ikemoto S, Narita K, et al: Interleukin-6, tumour necrosis factor alpha and interleukin-lbeta in patients with renal cell carcinoma. Br J Cancer. 2002; 86(9): 1396-1400
[139] Dunn AJ. Cytokinsasa bridage between immune and neuroendocrine system[J].Prog Neuroendocrine immunol, 1990, 3:26-34
[140] Blalock JE. A molecular basic for bidirectional communication between the immune and endocrine system[J]. Physiol Rev, 1989, 69(1):1-5
[141] Besedovsky HO, Sorkin E. Network of immune neuroendocrine interaction[J]. Clin Exp Immunol, 1991, 27:5-12
[142] BESEDOVSKY HA. DELREY, E. SORKIN, et al. Immunoregulatory feedback between interleukin- 1 and glucocorticoid hormones. Science. 1986; 233:652-654
[143] Foley, G E. Isolation and serial propagation of malignant and normal cells in semi-defined media origins of CCRF cells lines. Cancer Research. 1960, 20:930-938
[144] 施新秋，编著．医用实用动物学．陕西科技出版社．1989，243-245
[145] 张晓边．比较小鼠移植性肿瘤S180和S180A在抗癌药理中的作用．中国药理学会通讯．1995；12(3)：11-13
[146] 王秀芬．不同S180细胞株蛋白质特性的电泳及免疫组化研究得比较．实验动物科学与管理．2000；17(1)：7-9
[147] 高进，李敏明．中国人类免疫缺陷动物体内的模型建立及现存的问题．中华肿瘤杂志．1999；21(1)：69-72
[148] 顾文霞．小鼠瘤细胞免疫学的初步研究．生物化学杂志．1985；3(1)：65-71
[149] 金敬善，邓新荣，邹世洁．脾气虚证与神经分泌免疫网络相关性的研究．中国中医基础医学杂志，1997，3(3)：34-37
[150] BLALOCK, J. E., D. HARBUR-MCMENAMIN, E. M. SMITH. Peptide hormones shared by the neuroendocrine and immunologic systems. J. Immunol. 135, Suppl.: 1985, 858s-861s
[151] Sch PJ. Stress and cancer in: Cary L Cooper. Psychosocial Stress and Cancer. Jone Wiley & Sons Ltd, 1984
[152] ZHOU, D., A. W. KUSNECOV, M. R. SHURIN, M. DEPAOLI, AND B. RABIN. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 1993, 133: 2523-2530
[153] 王文芳，姚立人．应急对肿瘤转移的影响及免疫机制[J]．癌症，1992，11(2)：107-120
[154] 艾斯卡尔·依米提，哈木拉提·吾甫尔，布再娜甫·伊力哈木．维吾尔医成熟及清除剂诱导T淋巴瘤细胞凋亡的研究，中药药理与临 床．2000，2：36-38
[155] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木．维医成熟、清除剂诱导人Hela细胞凋亡时p53与bcl-2基因的表达．新疆医科大学学报．2000，1：57-60
[156] 哈木拉提，阿不都热依木，阿不都艾尼等．维吾尔医成熟剂和清除剂抗活性氧的作用研究．中国民族医药杂志．2000，3：54-56
[157] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木江·沙比提．异常黑胆质成熟剂与清除剂对人Hela细胞凋亡基因表达的影响．细胞与分子免疫学志．2001；2：112-114．
[158] 哈木拉提·吾甫尔，艾斯卡尔·依米提，伊力哈木江·沙比提等．维吾尔族异常黑胆质型患者基因多态性研究．中华医学遗传学杂志．2003；1(3)：540-550
[159] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，141-144
[160] 哈木拉提．吾甫尔．维吾尔医气质、体液论及其现代研究[M]，2003，166-170
[161] Hu J, Chen Z, Gorczynski CP, et al. Sleep-deprived mice show altered eytokine production manifest by perturbations in serum IL-lra, TNFa, and IL-6 levels. Brain Behav Immun. 2003 Dec; 17(6):498-504
[162] MATTA, S. G., J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1 β. Neuroendocrinology 1992, 56:516-525
[1] 顾宏涛．细胞防护剂WR-2721研究进展[J]．囡外医学放射医学核医学分册，2003，27：135-137
[2] 哈木拉提．吾甫尔．异常黑胆质成熟剂和清除剂体内外抗氧化功能的研究[M]．维吾尔医气质、体液论及其现代研究，2003，100-115
[3] 赵文仲，沈建良．甾体雌激素在放射损伤性造血重建中的作用机理[J]．中华放射医学与防护杂志，1991，11(1)：8
[4] 杨世海，尹春梅，缪双红．银耳多糖及其药理作用的研究进展[J]．中草药，1993，24(3)：153
[5] 梅其炳，陶静仪，张惠迪等．当归多糖对照射小鼠造血干细胞的影响[J]．中国药理学报，1988，9(3)：279
[6] Hari KUMAR.K.B, Sabu. M.C. Modulation of Haematopoetic System and Antioxidant Enzymes by Emblica officinal is gerent and its protective Role Against r-radiation induced damages in Mice[J]. Radiate Res, 2004, 45:549-555
[7] 哈木拉提．吾甫尔．异常黑胆质成熟剂和清除剂对DNA辐射损伤的保护作用研究[M]．维吾尔医气质、体液论及其现代研究，2003，122-124
[8] Bump, E.A. Brown.J.M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo (J). Pharmacologic.Ther. 1990, 47:117-120
[9] Tannehil, S.P. Metha, M.E Amifostine and radiation therapy: past, present and future. Semin[J]. Oncol. 1996, 28:8-69
[10] 徐冰心，肖成荣，郑思新等．辐射防护及研究进展[J]．中华放射医学与防护杂志，2002，22：64-69
[1] ADDISON, T. On the Constitutional and Local Effects of the Suprarenal Capsules. London: Highley, 1855.
[2] HENCH, P. S., E. C. KENDALL, C. H. SLOCUMB, AND H. F. POLLEY. The effect of a hormone of the adrenal cortex (17-hydroxycorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clinic Proe. 1949,24: 181-197.
[3] MCEWAN, B. S., C. A. BIRON, K. W. BRUNSON, et al. The role of adrenocortieoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Rev. 1997,23:79-133.
[4] BESEDOVSKY, H., E. SORKIN, M. KELLER, et al. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 1975, 150: 466-470.
[5] BESEDOVSKY, H. O., A. DEL REY, E. SORKIN. Lymphokine- containing supernatants from Con A-stimulated cells increase corticosterone blood levels. J. Immunol. 1981, 126: 385-387.
[6] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955.
[7] BESEDOVSKY, H., A. DEL REY, E. SORKIN, et al. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233: 652-654
[8] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955
[9] BRISTULF, J., A. SIMONCSITS, T. BARTFAI. Characterization of a neuronal interleukin-1 receptor and the corresponding mRNA in the mouse anterior pituitary cell line AtT-20. Neurosci. Lett. 1991, 128: 173-176
[10] ATKINS, E. Pathogenesis of fever. Physiol. Rev. 1986, 40: 580-646
[11] KLUGER, M. J. Fever: role of pyrogens and cryogens. Physiol. Rev. 1991,71:93-127
[12] BERKENBOSCH, F., D. E.C. DEGOEIJ, A. DEL REY, et al. Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. Neuroendocrinology 1989, 50: 570-576.
[13] BESEDOVSKY, H. O., A. DEL REY. Immune-neuroendocrine interactions: facts and hypotheses. Endocr. Rev. 1996, 17: 64-102
[14] KENT, S., J. L. BRET-DIBAT, K. W. KELLEY, et al. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci. Biobehav. Rev. 1996, 20: 171-175
[15] KRUEGER, J. M., AND J. A. MAJDE. Cytokines and sleep. Int. Arch. Allergy Immunol. 1995, 106: 97-100
[16] COHEN, M. C, AND S. COHEN. Cytokine function. A study in biological diversity. Am. J. Clin. Pathol. 1996, 105: 589-598
[17] PAUL, W. E.. Pleiotropy and redundancy: T-cell derived lymphokines in the immune response. Cell 1989, 57: 521-524
[18] KISHIMOTO, T., T. TAGA, AND S. AKIRA. Cytokine signal transduction. Cell 1994, 76: 253-262
[19] SATO, N., AND A. MIYAJIMA. Multimeric cytokine receptors: common versus specific functions. Curr. Opin. Cell Biol. 1994 ,6: 174-179
[20] OPP, M. R., AND J. M. KRUEGER. Anti-interleukin-1β reduces sleep and sleep rebound after sleep deprivation in rats. Am. J. Physiol. 266(Regulatory Integrative Comp. Physiol. 1994, 35: R688-R695
[21] CANNON, J. G, R. A. FIELDING, M. A. FIATARONE, et al. Increased interleukin-1 beta in human skeletal muscle after exercise. Am. J. Physiol. 257(Regulatory Integrative Comp. Physiol. 1989, 26: R451-R455
[22] CANNON, J. G, C. A. DINARELLO. Increased plasma interleukin-1 activity in women after ovulation. Science. 1985, 227: 1247-1249
[23] DINARELLO, C. A.The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163: 1177-1184
[24] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supresses' induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[25] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supress's induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[26] RIVIER, C., P. M. PLOTSKY. Mediation by corticotropin- releasing factor (CRF) of adenohypophysial hormone secretion. Annu. Rev. Physiol. 1986, 48: 475-494
[27] TURNBULL, A. V., AND C. RIVIER. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein and related peptides. Proc. Soc. Exp. Biol. Med. 1997,215: 1-10
[28] VALE, W., J. SPEISS, C. RIVIER,et al. Characterization of a 41-amino acid residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science .1981, 213: 1394-1397
[29] KELLER-WOOD, M. E., M. F. DALLMAN. Corticosteroid inhibition of ACTH secretion. Endocr. Rev. 1984, 5: 1-24
[30] MORGAN, J. I., AND T. CURRAN. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes FOS and jun. Annu. Rev. Neurosci. 1991, 14: 421-451
[31] BAN, E., L. SARLIEVE, F. HAOUR. Interleukin-1 binding sites on astrocytes. Neuroscience. 1993, 52: 725-733
[32] MATTA, S. G, K. M. LINNER, AND B. M. SHARP. Interleukin-1β and interleukin-1β stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology. 1993,57:14-22
[33] NAITO, Y., J. FUKATA, T. TOMINAGA, et al. Adrenocorticotropic hormone releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res. Commun. 1989, 164: 1262-1267
[34] SCHOTANUS, K., R. H. MELOEN, W. C. PUJIK, et al. Effects of monoclonal antibodies to specific epitopes of rat interleukin-1 beta (IL-1β) on IL-1β-induced ACTH corticosterone and IL-6 responses in rats. J. Neuroendocrinol. 1995, 7: 255-262
[35] SCHMIDT, E. D., A. W.J.W. JANSZEN, F. G. WOUTERLOOD, et al. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J. Neurosci. 1995, 15: 7417-7426
[36] NAITO, Y., J. FUKATA, S. NAKAISHI, et al. Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 1990, 51: 637-641
[37] SWEEP, C. G.J.F., M. J.M. VAN DER MEER, A. R.M.M. HERMUS, et al. Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1β infusion: in vivo and in vitro studies. Endocrinology 1992, 130: 1153-1164
[38] VAN DER MEER, M. J.M., C. G.J.F. SWEEP, G. J. PESMAN, et al. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine1996, 8: 910-919
[39] MATTA, S. G, J. WEATHERBEE, B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56: 516-525
[40] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, et al. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992,6:214-222
[41] CURTI, B. D., W. J. URBA, D. L. LONGO, et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996,19:142-148
[42] MASTORAKOS, G, G P. CHROUSOS, J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[43] NOLTEN, W. E., D. GOLDSTEIN, M. LINDSTROM, et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J. Interferon Res. 1993, 13: 349-357
[44] HERSEY, P, A. COATES, M. RALLINGS, et al. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanomas. J. Biol. Response Modif. 1986, 5: 236-249
[45] MASTORAKOS, G., G. P. CHROUSOS, J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[46] MASTORAKOS, G, J. S. WEBER, M.A. MAGIAKOU, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J. Clin. Endocrinol. Metab. 1994,79: 934-939
[47] MASTORAKOS, G, G. P. CHROUSOS, AND J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77: 1690-1694
[48] DUNN, A. J., M. L. POWELL, C. MEITIN, et al. Virus infection as a stressor: influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol. Behav. 1989, 45: 591-594
[49] RIVIER, C. Effect of peripheral and central cytokines on the hypothalamo-pituitary-adrenal axis of the rat. Ann. NY Acad. Sci. 1993,697:97-105
[50] DUNN, A. J., S. L. VICKERS. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994,645: 103-112
[51] RUZEK, M. C, A. H. MILLER, S. M. OPAL, et al. Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J. Exp. Med. 1997, 185: 1185-1192
[52] TURNBULL, A. V., C. RIVIER. Intracereboventricular (icv) passive immunization I: the effect of icv administration of an antisera to tumor necrosis factor-α on the plasma ACTH response to lipopolysaccharide in rats. Endocrinology 1998, 139:119-127
[53] LUHESHI, G, A. J. MILLER, S. BROUWER, et al. Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am. J. Physiol. 270(Endocrinol. Metab. 1995 ,33: E91-E95
[54] SMITH, B. K., AND M. J. KLUGER. Human IL-1 receptor antagonist partially suppresses LPS fever but not plasma levels of IL-6 in Fisher rats. Am. J. Physiol. 263(Regulatory Integrative Comp. Physiol. 1992, 32: R653-R655
[55] COOPER, A. L., S. BROUWER, A. V. TURNBULL, et al. Tumor necrosis factor-alpha and fever after peripheral inflammation in the rat. Am. J.Physiol. 267(Regulatory Integrative Comp. Physiol. 1994, 36:R1431-R1436
[56] GERSHENWALD, J. E., Y. FONG, T. J. FAHEY, et al. Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc. Natl. Acad. Sci. USA 1990, 87: 4966-4970
[57] WUSTEMAN, M., D. G.D. WIGHT, M. ELIA. Protein metabolism after injury with turpentine: a rat model for clinical trauma. Am. J. Physiol. 259(Endocrinol. Metab. 1990, 22: E763-E769
[58] SMITH, M. A., S. MAKINO, S. Y. KIM, et al. Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 1995, 136: 3743-3750
[59] ZHOU, D., A. W. KUSNECOV, M. R. SHURIN, M. DEPAOLI, AND B. RABIN. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of the hypothalamo-pituitary-adrenal axis. Endocrinology,1993,133: 2523-2530
[60] SHIZUYA, K., T. KOMORI, R. FUJIWARA, et al. The influence of restraint stress on the exposure of mRNAs for IL-6 and the IL-6 receptor in the hypothalamus and midbrain of the rat. Life Sci. 1997,61:135-140
[61] HOPKINS, S. J., N. J. ROTHWELL. Cytokines and the nervous system I: expression and regulation. Trends Neurosci. 1995,18: 83-88
[62] SEI, Y, L. VITKOVIC, M. M. YOKOYAMA. Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Neuroimmunomodulation 1995, 2: 121-133
[63] FARRAR, W. L., P. L. KILIAN, M. R. RUFF, et al. Visualization and characterization of interleukin 1 receptors in brain. J. Immunol. 1987, 139:459-463
[64] TOMOZAWA, Y, T. INOUE, M. SATOH. Expression of type I interleukin-1 receptor mRNA and its regulation in cultured astrocytes. Neurosci. Lett. 1995, 195: 57-60
[65] TAISHI, P., S. BREDOW, N. GUHA-THAKURTA, F. O. OBAL, AND J. M. KRUEGER. Diurnal variations of interleukin-1β mRNA and β-actin mRNA in rat brain. J. Neuroimmunol. 1997, 75: 69-74
[66] HOPKINS, S. J., N. J. ROTHWELL. Cytokines and the nervous system I: expression and regulation. Trends Neurosci. 1995, 18: 83-88
[67] SCHOBITZ, B., E. R. DE KLOET, F. HOLSBOER. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog. Neurobiol. 1994, 44: 397-432
[68] MURAMAMI, N., J. FUKATA, T. TSUKADA.et al. Bacterial lipopolysaccharide-induced expression of interleukin-6 messenger ribonucleic acid in the rat hypothalamus, pituitary, adrenal gland, and spleen. Endocrinology 1993, 133: 2574-2578
[69] SWIERGIEL, A. H., A. J. DUNN, AND E. A. STONE. The role of cerebral noradrenergic systems in the fos response to interleukin-1. Brain Res. Bull. 1996,41:61-64
[70] NIIMI, M., M. SAT, Y. WADA, J. TAKAHARA, et al. Effect of central and continuous intravenous injection of interleukin-1β on brain c-fos expression in the rat: involvement of prostaglandins. Neuroimmunomodulation 1996, 3: 87-92
[71] ZELAZOWSKI, P., V. K. PATCHEV, E. B. ZELAZOWSKA, et al. Release of hypothalamic corticotropin-releasing hormone and arginine vasopressin by interleukin-1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res. 1993,631:22-26
[72] YASIN, S. A., A. COSTA, D. HUCKS, et al. Interleukin-induced vasopressin release is inhibited by L-arginine. Ann. NY Acad. Sci. 1993, 689: 693-695
[73] SAPOLSKY, R., C. RIVIER, G. YAMAMOTO, et al. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987, 238: 522-524
[74] VAN DER MEER, M. J.M, C. G.J. SWEEP, C. E.M. RIJNKELS, et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1β, TNFα and IL-6: a dose response study. J. Endocrinol. Invest. 1996, 19:175-182
[75] TAKAO, T., C. TOJO, T. NISHIOKA, et al. Reciprocal modulation of corticotropin-releasing factor and interleukin-1 receptors following ether-laparotomy stress in the mouse. Brain Res. 1994, 660: 170-174
[76] TAKAO, T., C. TOJO, T. NISHIOKA, et al. Stress-induced upregulation of pituitary interleukin-1 receptors is mediated by corticotropin-releasing factor. Life Sci. 1996, 59:165-168
[77] AKITA, S., J. WEBSTER, S. G. REN, et al. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J. Clin. Invest. 1995, 95: 1288-1298
[78] ARZT, E., G. STEIZER, U. RENNER, et al. Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J. Clin. Invest. 1992, 90: 1944-1951
[79] BERNHAGEN, J., T. CALANDRA, R. A. MITCHELL, et al. Macrohpage migration inhibitory factor (MIF) is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 1993,365:756-759
[80] BUCALA, R. Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shock. Immunol. Lett. 1994,43: 23-26
[81] CALANDRA, T., J. BERHAGEN, C. N. METZ, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995,377:68-71
[82] TURNBULL, A.V., C. R1VIER. Cytokines within the neuroendocrine system. Curr. Opin. Endocrinol. Diabetes 1996, 3: 149-156
[83] SPANGELO, B. L., A. M. JUDD, P. C. ISAKSON, et al. Interleukin-1 stimulates interleukin-6 release from rat anterior pitutary cells in vitro. Endocrinology 1991, 128: 2685-2692
[84] BILEZIKJIAN, L. M., A. L. BLOUNT, C. A. CAMPEN, et al. Activin-A inhibits proopiomelanocortin messenger RNA accumulation and adrenocorticotropin secretion of AtT20 cells. Mol. Endocrinol. 1991, 5: 1389-1395
[85] DE SOUZA, E. B., E. L. WEBSTER, D. E. GRIGORIADIS,et al. Corticotropin-releasing factor (CRF) and interleukin-1 receptors in the brain-pituitary-immune axis. Psychopharmacol. Bull. 1991, 25: 299-305.
[86] WEBSTER, E. L., D. E. TRACEY, E. B. DE SOUZA. Upregulation of interleukin-1 receptors in mouse AtT-20 pituitary cells following treatment with corticotropin-releasing factor. Endocrinology 1991, 129: 2796-2798
[87] CUNNINGHAM, E. T. JR., E.WADA, D.B.CARTER, et al. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J. Neurosci. 1992, 12:1101-1114
[88] PATH, G., S. R. BORNSTEIN. Interleukin-6 and interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82: 2343-2349.
[89] SCHULTZBERG, M., C. ANDERSSON, A. UNDEN, et al. Interleukin-1 in adrenal chromaffin cells. Neuroscience 1989, 30: 805-810
[90] CONTI, B., J. W. JAHNG, C. TINTI, et al. Induction of interferon-gamma inducing factor in the adrenal cortex. J. Biol. Chem. 1997, 272: 2035-2037
[91] SCHOBITZ, B., M. VAN DOBBELSTEEN, F. HOLSBOER,et al. Regulation of interleukin-6 gene expression in rat. Endocrinology 1993, 132: 1569-1576
[92] MURAMAMI, N., J. FUKATA, T. TSUKADA, et al. Bacterial lipopolysaccharide-induced expression of interleukin-6 messenger ribonucleic acid in the rat hypothalamus, pituitary, adrenal gland, and spleen. Endocrinology 1993, 133: 2574-2578
[93] GWOSDOW, A. R., M. S.A. KUMAR, H. H. BODE. Interleukin-1 stimulation of the hypothalamo-pituitary-adrenal axis. Am. J. Physiol. 258(Endocrinol. Metab. 1990, 21: E65-E70
[94] DARLING, G, D. S. GOLDSTEIN, R. STULL, et al. Tumor necrosis factor: immune endocrine interaction. Surgery. 1989,106: 1155-1160
[95] PATH, G., AND S. R. BORNSTEIN. Interleukin-6 and interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82: 2343-2349
[96] GISSLINGER, H., T. SVOBODA, M. CLODI, et al. Interferon-alpha stimulates the hypothalamo-pituitary axis in vivo and in vitro. Neuroendocrinology 1993, 57: 489-495
[97] VAN DER MEER, M, C. G.J. SWEEP, C. E.M. RIJNKELS, et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1β, TNFα and IL-6: a dose response study. J. Endocrinol. Invest. 1996,19:175-182
[98] SARLIS, N. J., A. STEPHANOU, R. A. KNIGHT, et al. Effects of glucocorticoids and chronic inflammatory stress upon anterior pituitary interleukin-6 mRNA in the rat. Br. J. Rheumatol. 1993, 32: 653-657
[99] SPRENGER, H., C. JACOBS, M. NAIN, et al. Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running. Clin. Immunol. Immunopathol. 1992, 63: 188-195
[100] ZIELENIEWSKI, W., J. ZIELENIEWSKI, H. STEPIEN. Effect of Interleukin-1α, IL-1β and IL-1 receptor antibody on the proliferation and steroidogenesis of regenerating rat adrenal cortex. Exp. Clin. Endocrinol. Diabetes 1995, 103: 373-377
[101] Gaillard RC. Intreactions between the immune and neuroendocrine system: clinical implications. J Scol Biol. 2003:197(2):89-95
[102] ThyagaRajan S, Felten DL.Modulation of neuroendocrine-immune signaling by L-deprenyl and L-desmethyLdeprenyl in aging and mammary cancer.Mdch Ageing Dev. 2002 Apr 30:123(8): 1065-79
[103] John CD, Buckingham JC. Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Curr Opin Pharmacol. 2003 Feb;3(1):78-84
[104] Corcos M,Guilbaud O,Paterniti S.Moussa M,Chaouat G,Consoli SM, Jeammet P.Involvement of cytokines in eating disorders: a critical review of the human literature. Psychoneuroendocrinology. 2003 Apr; 28(3):229-49
[105] Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002; 20:125-63. Epub 2001 Oct 04
[106] Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic- pituitary-adrenal revolving axis. J Neuroimmunol. 2003 Dec; 145(1-2):154
[1] SELLMEYER, D. E., and C. GRUNFIELD. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr. Rev. 1996, 17:518-532
[2] JAFFE, H. L. The influence of the suprarenal gland on the thymus. III. Stimulation of the growth of the thymus gland following double suprarenalectomy in young rats. J. Exp. Med. 1924, 40: 753-760
[3] ADDISON, T. On the Constitutional and Local Effects of the Suprarenal Capsules. London: Highley, 1855
[4] HENCH, P. S., E. C. KENDALL, C. H. SLOCUMB, AND H. F. POLLEY. The effect of a hormone of the adrenal cortex (17-hydroxycorticosterone: compound E) and of pituitary adrenocorticotropic
[5] SELYE, H. Thymus and adrenals in the response of the organism to injuries and intoxications. Br. J. Exp. Pathol. 1936, 17: 234-248
[6] MUNCK, A., P. M. GUYRE, AND N. J. HOLBROOK. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 1984, 5: 25-44
[7] DEL REY, A., H. BESEDOVSKY, AND E. SORKIN. Endogenous blood levels of corticosterone control the immunologic cell mass and B cell activity in mice. J. Immunol. 1984, 133: 572-575
[8] BESEDOVSKY, H., E. SORKIN, M. KELLER, AND J. MULLER. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 1975, 150: 466-470
[9] BESEDOVSKY, H. O., A. DEL REY, AND E. SORKIN. Lymphokine-containing supernatants from Con A-stimulated cells increase corticosterone blood levels. J. Immunol. 1981, 126: 385-387
[10] MCEWAN, B. S, BIRON, K. W. BRUNSON, K. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Rev. 1997,23:79-133
[11] SMITH, E. M, AND J. E. BLALOCK. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. USA .1981,78:7530-7534
[12] BESEDOVSKY, H., A. DEL REY, E. SORKIN, AND C. A. DINARELLO. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233: 652-654
[13] HEALY, D. L., G. D. HODGEN, H. M. SCHULTE, et al, ethymus-adrenal connection: thymosin has corticotropin-releasing activity in primates. Science 1983, 222: 1353-1355
[14] MCGILLIS, J. P., N. R. HALL, G. V. VAHOUNY, et al. Thymosin fraction 5 causes increased serum corticosterone in rodents in vivo. J. Immunol. 1985, 134: 3952-3955
[15] BRODISH, A. Extra-CNS corticotropin-releasing factors. Ann. NY Acad. Sci. 1977, 297: 420-435
[16] BRODISH, A.. Tissue corticotropin releasing factors. Federation Proc. 1977,36:2088-2093
[17] LYMANGROVER, J. R., AND A. BRODISH. Tissue CRF: an extrahypothalamic corticotropihin releasing factor (CRF) in peripheral blood of stressed rats. Neuroendocrinology 1973, 12: 225-235
[18] WOLOSKI, B.M.R.N. J., E.M. SMITH, et al. Corticotropin-releasing activity of monokines. Science. 1985,230: 1035-1037
[19] BLALOCK, J. E. The syntax of immune-neuroendocrine communication. Immunol. Today. 1994, 15: 504-511
[20] BLALOCK, J. E., D. HARBUR-MCMENAMIN, AND E. M. SMITH. Peptide hormones shared by the neuroendocrine and immunologic systems. J. Immunol. 1985, 135, Suppl.: 858s-861s
[21] DUNN, A. J., M. L. POWELL, AND J. M. GASKIN. Virus-induced increases in plasma corticosterone. Science. 1987, 238: 1423-1424
[22] DUNN, A. J., AND S. L. VICKERS. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994, 645: 103-112
[23] SMITH, E. M., AND J. E. BLALOCK. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. USA.1981,78:7530-7534
[24] SMITH, E. M., M. PHAN, T. E. KRUGER, D. H. COPPENHAVER, AND J. E. BLALOCK. Human lymphocyte production of immunoreactive thyrotropin. Proc. Natl. Acad. Sci. USA. 1983, 80: 6010-6013
[25] WEIGENT, D. A., AND J. E. BLALOCK. Interaction beteen neuroendocrine and immune systems: common hormones and receptors. Immunol. Rev. 1987, 100: 79-108
[26] WEIGENT, D. A., AND J. E. BLALOCK. Production of peptide hormones and neurotransmitters by the immune system. Chem. Immunol. 1997,69: 1-30
[27] OLSEN, N. J., W. E. NICHOLSON, C. R. DEBOLD, et al. Lymphocyte-derived adrenocorticotropin is insufficient to stimulate adrenal steroidogenesis in hypophysectomized rats. Endocrinology 1992,130: 2113-2119
[28] COHEN, M. C., AND S. COHEN. Cytokine function. A study in biological diversity. Am. J. Clin. Pathol. 1996, 105: 589-598
[29] PAUL, W. E.. Pleiotropy and redundancy: T-cell derived lymphokines in the immune response. Cell 1989, 57: 521-524
[30] ISHIMOTO, T., T. TAGA, AND S. AKIRA. Cytokine signal transduction. Cell 1994,76: 253-262
[31] SATO, N., AND A. MIYAJIMA. Multimeric cytokine receptors: common versus specific functions. Curr. Opin. Cell Biol. 1994, 6: 174-179
[32] OPP, M. R., AND J. M. KRUEGER. Anti-interleukin-1β reduces sleep and sleep rebound after sleep deprivation in rats. Am. J. Physiol. 266(Regulatory Integrative Comp. Physiol. 1994, 35: R688-R695
[33] CANNON, J. G., R. A. FIELDING, M. A. FIATARONE, S. F. ORENCOLE, C. A. DINARELLO, AND W. J. EVANS. Increased interleukin-1 beta in human skeletal muscle after exercise. Am. J. Physiol. 257(Regulatory Integrative Comp. Physiol. 1989, 26: R451-R455
[34] CANNON, J. G, AND C. A. DINARELLO. Increased plasma interleukin-1 activity in women after ovulation. Science. 1985, 227: 1247-1249
[35] DINARELLO, C. A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163: 1177-1184
[36] JORDAN, M., I. G. OTTERNESS, R. NG, et al. Neutralization of endogenous IL-6 supresses' induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[37] ORDAN, M., I. G. OTTERNESS, R. NG, A. GESSNER, M. ROLLINGHOFF, AND H. U. BEUSCHER. Neutralization of endogenous IL-6 supress's induction of IL-1 receptor antagonist. J. Immunol. 1995, 154: 4081-4090
[38] VAN DER MEER, M. J.M., C. G.J.F. SWEEP, et al. HERMUS. Chronic stimulation of the hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine. 1996,8:910-919
[39] MATTA, S. G, J. WEATHERBEE, AND B. M. SHARP. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1β. Neuroendocrinology 1992, 56: 516-525
[40] HARBUZ, M. S., A. STEPHANOU, R. A. KNIGHT, A. J. CHOVER-GONZALEZ, AND S. L. LIGHTMAN. Action of interleukin-2 and interleukin-4 on CRF mRNA in the hypothalamus POMC mRNA in the anterior pituitary. Brain Behav. Immun. 1992, 6:214-222
[41] CURTI, B. D., W. J. URBA, D. L. LONGO,et al. Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996, 19: 142-148
[42] MASTORAKOS, G, G. P. CHROUSOS, AND J. S. WEBER. Recombinant interleukin-6 activates the hypothalamic-pituitary- adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993 , 77: 1690-1694
[43] NOLTEN, W. E., D. GOLDSTEIN, M. LINDSTROM,et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J. Interferon Res. 1993, 13: 349-357
[44] HERSEY, P., A. COATES, M. RALLINGS,et al. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanomas. J. Biol. Response Modif. 1986, 5: 236-249